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Inﬂammation is implicated in tumor development, invasion, and metastasis. Hence, it has been suggested that common cellular
and molecular mechanisms are activated in wound repair and in cancer development. In addition, it has been previously proposed
that the inﬂammatory response, which is associated with the wound healing process, could recapitulate ontogeny through the
reexpression of the extraembryonic, that is, amniotic and vitelline, functions in the interstitial space of the injured tissue. If so, the
use of inﬂammation by the cancer-initiating cell can also be supported in the ability to reacquire extraembryonic functional axes
for tumor development, invasion, and metastasis. Thus, the diverse components of the tumor microenvironment could represent
the overlapping reexpression of amniotic and vitelline functions. These functions would favor a gastrulation-like process, that is,
the creation of a reactive stroma in which ﬁbrogenesis and angiogenesis stand out.
1.Introduction
In the nineteenth century, Rudolf Virchow postulated a link
between cancer and inﬂammation on the basis of observa-
tions that tumors often arose at sites of chronic inﬂamma-
tion, and the inﬂammatory cells were present in biopsied
samples from tumors [1]. Twenty-ﬁve years ago, Dvorak
recognized that the composition of tumor stroma is very
similar to that of granulation tissue of healing skin wounds.
He therefore suggested that “tumors are wounds that do not
heal” [2]. Since that time, inﬂammation has been implicated
in tumor development, invasion, and metastasis and in the
development of clinical features as fever and cachexia [3].
These observations suggested that common cellular and mo-
lecular mechanisms are active in wounds and in cancer tissue
[4].
2. Wound Repair Phenotypes:
GastrulationRevisited
The inﬂammatory response that is induced in the injured
skin could be described as a succession of three overlapping
phases during which the phenotypes of metabolic progres-
sive complexity in using oxygen are expressed. Each one of
these phases emphasizes the trophic role of the mechanisms
developed in the damaged tissue. Hence, nutrition by diﬀu-
sion predominates in the ﬁrst phase; trophism is mediated
by inﬂammatory cells in the second phase and ﬁnally blood
circulation and oxidative metabolism play the most signiﬁ-
cant nutritive role in the third phase [5].
In the ﬁrst or immediate phase of the inﬂamma-
tory response, interstitial hydroelectrolytic alterations stand
out. The vasomotor response, with vasoconstriction and2 Journal of Oncology
Table 1: Phenotypes expressed in the acute inﬂammatory wound
healing response.
(i) Ischemia-reperfusion phenotype
(a) Oxidative and nitrosative stress
(b) Interstitial hydroelectrolytic alterations
(c) Increased lymphatic circulation (circulatory switch)
(ii) Leukocytic phenotype
(a) Inﬁltration by granulocytes and agranulocytes
(macrophages-lymphocytes)
(b) Lymphangiogenesis
(c) Lymph node reaction
(d) Wound immunotolerance
(e) Resolution
(iii) Angiogenic phenotype
(a) Endothelial cell proliferation
(b) Fibrogenesis
(c) New vascular network
(d) Epithelial regeneration
vasodilation,isresponsiblefortheischemia-reperfusionphe-
nomenon, which in turn causes oxidative and nitrosative
stress in the injured tissue. In this phase, during the pro-
gression of the interstitial edema, the lymphatic circulation
is simultaneously activated. In the following intermediate
phaseoftheinﬂammatoryresponse,thetissuesareinﬁltrated
by inﬂammatory blood-born cells, particularly leukocytes.
Symbiosis of the leukocytes and bacteria for extracellular
digestion by enzyme release, that is, phagocytosis, produces
enzymatic stress. Furthermore, macrophages and dendritic
cells take advantage of the lymphatic circulation activation
and migrate through it until reaching the lymph nodes,
where they activate lymphocytes [5, 6].
During the third phase of the inﬂammatory response,
angiogenesis permits numerous substances, including hor-
mones, to be transported by the blood circulation. Although
the ﬁnal objective of angiogenesis is to form new mature
vessels for oxygen, substrates, and blood cell transport, other
functions could be carried out before the new mature vessels
are formed. Thus, angiogenesis could have antioxidant and
antienzymatic properties, favoring therefore the resolution
of the inﬂammation, as well as wound repair by epithelial
regeneration and scarring. Consequently, in this phase the
new formed tissue is structured, specialized, and matured by
remodeling [5–7]( Table 1).
It has been previously proposed that the inﬂammatory
response associated with the wound healing process in the
skin could recapitulate ontogeny through the reexpression of
two hypothetical embryonic trophic axes, that is, amniotic
andyolksacorvitelline,intheinterstitialspaceoftheinjured
tissue. If so, inﬂammation could represent the debut during
postnatal life of ancestral biochemical mechanisms that were
used for normal embryonic development. The re-expression
of these ancient mechanisms, with a prenatal solvent path,
is perhaps inappropriate and hard to recognize since they
are anachronistic during postnatal life and because they are
established in a diﬀerent environmental medium [8].
Themolecularandcellularcontributionmadebythetwo
extraembryonic tissues that surround the fetus, the amnion
and yolk sac, to the interstitial space located between them,
namely, the mesoderm, are essential for organogenesis [9].
It could be assumed that both cavities are controlled by an
arrayofinductive andinhibitory signalsoriginating fromthe
adjacent extraembryonic mesenchyma [8]( Figure 1).
The amniotic axis could play a leading role in primitive
interstitial hydroelectrolytic changes. The early mammalian
embryo already has the ability to manage ﬂuids in the in-
terstitial space. Body ﬂuid is distributed among three major
ﬂuid spaces, that is, intracellular ﬂuid, interstitial ﬂuid, and
plasma. Nevertheless, the ﬂuid distribution in each of these
compartmentsisdramaticallydiﬀerentinthefetuscompared
to the adult. Particularly, the amniotic ﬂuid that surrounds
the fetus may be considered an extension of the extracellular
space of the fetus. Thus, the lymphatic system plays an es-
sential role in the regulation of ﬂuid distribution between
the plasma and the interstitial ﬂuid and, probably, with
the amniotic ﬂuid [10]. In addition to the rich amino acid
content, amniotic ﬂuid contains abundant peptides, car-
bohydrates, lipids, hormones, and electrolytes with water
[11]. The amniotic ﬂuid has antimicrobial properties, and
this may be part of the innate immune system. A reduced
volume of amniotic ﬂuid may decrease the natural host de-
fense conferred by this ﬂuid and predispose it toward in-
trauterine infections [12]. Finally, it has been shown that
amniotic-ﬂuid-derivedstemcellsareabletodiﬀerentiateinto
neurogenic, mesodermal, and endodermal lineages [13].
The vitelline axis, represented by the yolk sac, is the ﬁnal
destinationofmigratingvisceralendodermcells.Thevisceral
yolk sac expands, and blood islands, structures consisting
of hematopoietic progenitors surrounded by a loose network
of endothelial cells, appear [14]. Endothelial cell precursors
associated with blood islands diﬀerentiate and coalesce to
form a primitive circulatory bed, which later connects to
the embryo via the vitelline vessels [15]. Also, a major func-
tion of the yolk sac is the accumulation of carbohydrates,
proteins, and lipids (vitellum) for embryo nutrition [16, 17].
Particularly, the yolk sac plays a vital role in providing lipids
and lipid-soluble nutrients to embryos during the early
phases of development [16, 18]. The yolk sac uses high-
density lipoproteins (HDLs) and very-low-density lipopro-
teins (VLDL) as carriers to incorporate cholesterol from the
maternal circulation and to transfer it to the embryonic side
[16]. In turn, the interstitial lipid accumulation of choles-
terol, a precursor molecule of many hormones like aldos-
terone, corticoids, androgens, strogens, and progesterone,
may favor ﬂuid inﬁltration and cell migration, proliferation,
and diﬀerentiation during embryo development [19]. The
ability to transport fat in the form of lipoprotein through the
circulatory system by eukaryotes is one of their most signifi-
cant functions right from the beginning of existence [20].
It could be accepted that these primitive functions are
internalized during gastrulation to create the intraembry-
onic mesoderm. Thus, this germ layer would integrate the
amnion- and yolk-sac-related functions [8]. Fibroblasts areJournal of Oncology 3
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Figure 1: Representative drawing of the early mammalian embryo during gastrulation. The internalization of the extraembryonic mesoderm
(EM)duringgastrulationallowsforthecreationoftheintraembryonicmesoderm(IM)thatcouldthusjoinfunctionalamnioticandvitelline
properties from the amnion (A) and yolk sac (YS), respectively. BI: blood islands; C: chorionic vellosities.
mesodermalderivedcells,andperhapsthisembryonicorigin
could justify their great postnatal plasticity. The mesodermal
cells of the embryo participate in the extraembryonic struc-
tures, including the chorion, the amnion, and the yolk sac
[9]. In the human body, the ﬁbroblasts form a heterogeneous
collection of mesenchymal cells and they are the principal
cellular constituents of connective tissues [21]. The major
role of the mesodermal cells and their ability to diﬀerentiate
from the ﬁrst stages of embryonic development allow for
considering them as the cell prototype that should be re-
sorted to when the repair of any tissue in the body is needed
[9]. And for this reason, perhaps the posttraumatic inﬂam-
matory response after a skin wound has the same intention,
namely, to use the embryonic mesodermal phenotype with a
therapeutic objective [8].
Local ﬁbroblasts residing in the skin are considered the
mostprominentsourceofmyoﬁbroblasts.However,avariety
of other precursor cells contribute to the myoﬁbroblast pop-
ulation,dependingonthenatureoftheinjuredtissueandthe
particular microenvironment [22]. Activated myoﬁbroblasts
are generated from a variety of sources, including resident
mesenchymal cells, epithelial and endothelial cells, via the
epithelial/endothelialmesenchymaltransitionaswellasfrom
circulatingﬁbroblast-likecellscalledﬁbrocytes,derivedfrom
bone marrow stem cells [21, 23]. In addition, circulating
monocytes have the capacity to diﬀerentiate into nonphago-
cytes, that is, mesenchymal cells and endothelial cells [24].
The reason why the myoﬁbroblasts are attractive to a
broadscientiﬁc and clinical audienceis due to thelargepanel
of cells that can develop this phenotype upon activation.
It appears that myoﬁbroblasts can be recruited from any
local cell type and they are suitable for rapidly repairing
injured tissue [22]. Fibroblasts can be induced to acquire the
myoﬁbroblast phenotype during wound repair. Several days
after injury, a subset of wound ﬁbroblasts can diﬀerentiate
into myoﬁbroblasts, which are responsible for repopulating
the wounded area in parallel to angiogenesis, thus forming
the granulation tissue [6, 7]. Granulation tissue is then
repopulated with ﬁbroblasts to produce a more densely
collagenous extracellular matrix which is more akin to the
matrix found in interstitial stroma [25].
Tissue remodeling requires the removal of granulation
tissue, and maturation of collagen is oxygen dependent [6].
Indeed increasing wound oxygenation results in increased
collagen deposition and tensile strength [26]. However, hyp-
oxiabeneﬁtstheexpansion,diﬀerentiation,adhesion,growth
factor secretion, and regenerative potential of mesenchymal
stem cells derived from subcutaneous adipose tissue [27].
Finally, the phenotypic changes suﬀered by the keratinocytes
during reepithelization suggest a partial epithelial-mesen-
chymal transition. Following the completion of wound re-
pair, keratinocytes revert from their mesenchymal-like phe-
notype to an epithelial phenotype [28, 29].
In the adult organism, many pathways that play an essen-
tial role during embryo development are inactivated later
in life although some of them may be transiently expressed
during adult repair [30]. That is why we have considered that
wound repair would require the upregulation of signaling
pathwayscharacteristicoftheextraembryonicfunctions,that
is,amniotic andvitelline,duringtheembryodevelopment.If
so, emulation by the wound tissue of these extraembryonic
functions perhaps requires retracing the mechanisms that
produce and distribute the extracellular ﬂuid and substrates;
activate the migration and invasion of stem or progenitor
cells and hematopoietic-derived cells, and induce the estab-
lishment of a complex vascular network by lymphangio-
genesis and angiogenesis; ﬁnally all of them are required to
mediate normal new tissue growth and development [8].
The above-mentioned extraembryonic mechanisms seem to
be aimed at favoring the grafting of new repaired tissue.
Thus, through the successive expression of functions related
to natural immunity and later with the acquired immunity,
the neoformed tissue is accepted by the host.
This transient recapitulation of embryonic mechanisms
through the hypothetical succession of overlapped amniotic-
like and vitelline-like functions would achieve the cellular
and metabolic diversity necessary for repairing the injured
adult tissue with a graft (Table 1).4 Journal of Oncology
3.The Inﬂammatory CancerCell
Nowadays, the causal relationship between inﬂammation
and cancer is widely accepted [1, 3, 4, 31–37]. Inﬂammation
has long been thought to have contributed to the develop-
ment of cancer [1, 35, 37]. And consequently, chronic in-
ﬂammation is a major cause of cancer [32, 34, 36].
The understanding of the pathogenesis and progres-
sion of cancer requires the establishment of the altered ge-
netic/metabolic factors that are essential to the development,
growth, and proliferation of malignant cells [38]. This new
frontier of cancer research requires the appropriate marriage
ofgenetic/proteomicstudiesorthegeneticistapproachtothe
biochemical/metabolic cellular studies or the biochemical
approach [38].
With regards to the geneticist approach, in many cancers
a stem cell tumor model probably takes place [39]. Although
a stem cell may sustain the ﬁrst oncogenic hit, subsequent
alterations required for the genesis of a cancer stem cell can
occurindescendentcells[40].Thismechanismcouldexplain
the marked tumoral heterogeneity, either interturmoral, that
is, variability between tumors arising in the same organ, or
intratumoral, that is, variability within individual tumors
[40].
With regards to the biochemist approach, metabolic
transformation of malignant cells is essential to the develop-
mentandprogressionofallcancers[38,41–43].Cancercells,
similartonormalcells,liveinnichesandmicroenvironments
that are heterogeneous. Speciﬁcally, intratumoral gradients
of nutrients and oxygen could play a profound role in mod-
ulating tumor cell metabolism [42].
The comparison of tumors with wounds that do not heal
[2] suggests that during the host invasion, the malignant
tumor cells could express the previously proposed inﬂam-
matory phenotypes during wound repair [44]. Due to the
plasticity of cancer stem cells, it should be kept in mind that
while a malignant tumor develops, it can express phenotypes
that also share the inﬂammatory response such as an
ischemic phenotype (hypoxic) with edema and lymphan-
giogenesis (circulatory switch) a leukocytic phenotype being
adapted, with migration to the regional lymph nodes and
development of cachexia, and an angiogenic phenotype with
the supply of nutrients and oxygen and tumoral mass growth
[44–46]( Figure 2).
It has already been proposed that these phenotypes
represent the expression of trophic functional systems of
increasing metabolic complexity in the wound inﬂammatory
response [5, 6]. Their expression by cancer cells could have a
similar signiﬁcance [46]. In this hypothetical circumstance,
malignant tumor cells could adopt an inﬂammatory-like
phenotypethatevolvesinthreehypotheticalfunctionalphas-
es of increasing metabolic complexity and which would also
have a trophic signiﬁcance [44–46].
Moreover,acutewounds areinitially hypoxic, andchron-
icischemicwoundsareessentiallyhypoxic[47,48].However,
in the wounded tissue molecular and functional heteroge-
neity could be related to the heterogeneous distribution of
oxygen with hypothetical pockets of graded levels of hypoxia
[48].
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Figure 2: Evolutive phases of the inﬂammatory cancer cell. Cancer
cells can adopt an inﬂammatory phenotype to invade neighboring
tissues and survive in these ectopic sites. In the successive phases
of tumorigenesis, the cancer cells invade the host by expressing
natural and adaptive immune-related mechanisms. sc: stem cell;
scc: stem cancer cell; shc: stem hematopoietic cell; f: ﬁbroblast; mn:
monocyte; mf: myoﬁbroblast; g: granulocyte; mØ: macrophage; lc:
lymphatic capillary; cc: cancer cell; lnm: lymph node metastasis;
hev: high endothelial venule; l: lymphocytes; pcv: postcapillary
venule; bc: blood capillary; p: pericyte; ∗tumoral antigen.
The hypothesized similarity of the inﬂammatory re-
sponse in wounds and tumors, based on the molecular-relat-
ed, that is, genetic and metabolic, pathways is an interesting
proposal because it could allow for translational inﬂamma-
tory research between tissue repair and cancer. Moreover, the
cancer cell also successively uses the natural and acquired
immunity to be grafted into the host. The need to be recog-
nized by the host, by both the cells that make the wound
repair and by the cells that cause tumorigenesis to develop,
would indicate that in the adult organism the creation of
a new tissue without a previous immunologic acceptation
could not be possible. Regardless of whether the neoformed
tissue is normal, like during embrionary development and
wound repair, or pathological, like in cancer, the expression
of extraembryonic functions would be essential for homing
in the host. Therefore, maybe the diﬀerent inﬂammatory-
related extraembryonic ways that converge in the embryo, in
thewoundrepairprocessandintumorgrowth,havetheﬁnal
aim of getting their immunological acceptation.
4. The EvolutivePhases of the Inﬂammatory
CancerCell
It has been proposed that the relation between inﬂammation
and tumor development depends on whether the tumor is
benign or malignant [44]. The benign tumor cells seem to
be able to induce the inﬂammatory response in the host.
Therefore, it is possible that the host participates in estab-
lishing the tumor through a process called desmoplasia,
which consists of ﬁbroblastic cells and the extracellular ma-
trix, a leukocytic response represented by lymphocytes, ma-
crophages, and dendritic cells, and lymphangiogenesis and
angiogenesis [49]. Essentially, all the elements that constitute
the inﬂammatory response participate in the “host reaction,”Journal of Oncology 5
which could, therefore, have a trophic purpose for the tumor
cells [44, 46]. Consequently, this inﬂammatory response of
the host would develop in the interstitial space of the tumor,
which invades in order to be more eﬃcient, trophically [46].
However, when tumor cells reach higher grades of malig-
nancy,theirinvasivecapacityreﬂectedintheclassicmetastat-
ic cascade, that is, primary tumor (T), lymph node invasion
(N), and distant metastases (M), seems to reﬂect a new ca-
pacity to express the inﬂammatory response more than to
induce it in the host [45]. In this hypothetical circumstance
the inﬂammatory phenotypes would be expressed by tumor
cells to invade the host.
Therefore, it should be kept in mind that while a ma-
lignant tumor develops it can express phenotypes that are
common to the inﬂammatory response, including a hypoxic
phenotype with edema and lymphangiogenesis, a leukocytic
phenotype with migration to the regional lymph nodes and
distant metastasis, and an angiogenic phenotype with granu-
lation tissue development and tumor and metastasis growth.
4.1. The Hypoxic Phenotype and the Interstitial-Lymphatic
Tumoral Axis. Hypoxia and inﬂammation meet at several
points in the setting of cancer [50]. During the initial avas-
cular stages of tumor growth, which is when the tumor mass
measures less than 0.5cm [51], the cells seem to adopt an
anoxic-hypoxic phenotype [52].Whentumorcellscomeinto
contact with oxygen, they could undergo a process of reox-
ygenation, with oxidative stress and edema [44].
The experimental evidence indicates that the cell mech-
anism for adapting to hypoxia is the prolyl-hydroxylase-
(PHD)-hypoxia-inducible transcription factor (HIF) system
[50]. The distribution of PHD-HIF system within the
inﬂamed tumor is involved in both its growth and vascular-
ization [50]. In this way, cancer cells could adopt a hypoxic
metabolism to survive. Most cancer cells rely on aerobic
glycolysis,aphenomenontermed“theWarburgeﬀect.”Thus,
cancer cells can convert glucose and glutamine into biomass
most eﬃciently and will proliferate faster [53]. In addi-
tion, glutamine metabolism has important “nonanabolic”
functions, including the regulation of oxidative stress, signal
transduction, and autophagy [43].
Cancer cells at this stage can overexpress matrix met-
alloproteinases (MMPs). In many instances, therefore, the
extensive alterations produced by MMPs in the stromal mi-
croenvironment could promote tumor progression [54, 55].
Thus, during the earlier phase of tumor progression, the
metabolic autonomy and invasive capacity of the tumor cells
would induce their premature migration to the peripheral
tissue [56].
Metabolically active cancer cells could induce interstitial
edema [57]. There is increasing evidence that conditions
characterized by an intense inﬂammatory response are asso-
ciated with alterations in cellular membrane potential, with
subsequent depolarization and abnormal ion transport.
Moreover, disturbances in ion transport are associated with
intracellular as well as interstitial edema [58]. Interstitial
ﬂuidﬂowiselevatedintumors,thusfavoringthediﬀusionof
solutes and proteins and inducing a substantial inﬂuence on
cancer cells [59, 60]. The tumor interstitial ﬂuid is absorbed
by lymphatic capillaries and drains through lymph nodes in
the thoracic duct, where it reaches the blood via the great
veins of the neck [60]. Tumor interstitial ﬂuid is suggested to
be a rich sample for discovering biomarkers [61].
Compared with nonneoplastic tissue, the tumor stroma
contains increased amounts of collagens, proteoglycans, and
glycosaminoglycans [61, 62]. The accumulation of glycos-
aminoglycan fragments especially has been proposed as an
important mechanism for edema formation because of its
hydrophilic properties [63]. Glycosaminoglycans, that is, hy-
aluronan, are long unbranched polysaccharide chains which
tend to adopt highly extended random-coil conformations
and occupy a huge volume for their mass [63]. They attract
and entrap water and ions, thereby forming hydrated gels,
while permitting the ﬂow of cellular nutrients [63]. Thus,
interstitial edema could favor nutrition by diﬀusion through
the malignant tumor. Under inﬂammatory conditions, hya-
luronan is more polydisperse with a preponderance of lower-
molecular forms and favors edematous inﬁltration of the
tissues as well as the interstitial ﬂuid ﬂow and the tissue
lymph pressure gradient [54, 63, 64].
Tumor interstitial ﬂuid represents the early microenvi-
ronment of the tumor cells [57, 59]. One may therefore
envisage that access to tumor interstitial ﬂuid bathing the
cancer cells is considerably important in order to understand
how tumors develop and progress [57, 59]. It could be sus-
pected that during this early phase of the inﬂammatory
cancer cell response, while edema progresses, the lymphatic
circulation is simultaneously activated and this circulatory
switch establishes an interstitial-lymphatic tumoral axis by
which lymph can reach the systemic blood circulation [60].
In this way, lymphatic tumoral vessels are transformed in
routes for traﬃcking through the body, exploited not only
by immune cells but also by cancer cells [65]. Nevertheless,
the interstitial tumoral ﬂuid ﬂow associated with edema
can have important eﬀects on tumoral tissue morphogenesis
and function, cancer cell migration, and diﬀerentiation, and
matrix remodeling, among other processes [66]( Figure 3).
A number of studies in animal tumor models have estab-
lished the concept that tumors, rather than just accidentally
invading preexisting lymphatic vessels in their vicinity,
can actively induce tumor-associated lymphangiogenesis by
s e c r e t i n ga p p r o p r i a t eg r o w t hf a c t o r s ,s u c ha sv a s c u l a re n d o -
thelial growth factor (VEGF)-C, VEGF-D, or VEGF-A [65].
The formation of new lymphatic vessels, termed lymphan-
giogenesis, is often observed around or within the tumors
[67]. With tumor progression, cancer cells secrete lymphan-
giogenic cytokines and growth factors which result in the
formation of lymphatic vessels [68]. Tumor-associated lym-
phangiogenesis leads to a more extensive drainage network
to capture the increased interstitial ﬂuid ﬂowing from the
tumor cells and through the microenvironment [60]. Lym-
phatic vessels are also active modulators of immunity. The
tumor associated with the lymphatic system may aﬀect not
only the local microenvironment, but also the host immune
response against the tumor [69]. Recent ﬁndings raise the
possibility that the tumor-associated lymphatic vessel and
draininglymphnodesmaybeimportantintumorimmunity,6 Journal of Oncology
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Figure 3: Successive and overlapped stages of tumorigenesis. Genetic and epigenetic factors stimulate the formation of a cancer stem cell that
invades the interstitial space favored by the inﬂammatory interstitial-lymphatic axis, which stands out the tissue circulation of ﬂuid and the
cellularmigration.Thetumorcell,bymeansofusingthenaturalandadaptiveimmunemechanisms,becomesimmunotolerant,whichfavors
the following phases of tumor development. Then, the cancer cell induces the creation of a stroma formed by a special type of granulation
tissue, and this allows for the creation of a tumoral parenchyma provided with functional heterogeneity. Finally, this heterogeneous tumor
mass plunders the trophic stores of the host inducing cachexia.
which in turn govern metastasis. Peritumoral lymphangio-
genesis associated with increased drainage to the lymph
nodes could activate and maintain tumor tolerance by the
host[69].Hence,targetinglymphangiogenesisbydeveloping
antilymphangiogenesis agents might constitute a novel way
to prevent lymphatic progression in some tumors [70].
It has been shown that tumoral lymphatic vessels could
displayaretrogradedrainingpattern.Today,themechanisms
of tumoral lymphatic dysfunction are not entirely known
[68].Itishypothesizedthattherapidgrowthoftumorresults
in tissue edema, which generates mechanical forces to com-
press the lymphatics, or tumor cells can destroy the intra-
tumoral lymphatic structure [68]. However, the high colloid
osmotic pressure and protein concentration of the tumoral
interstitial ﬂuid [59] associated with the tumoral lymphatic
dysfunction could favor cancer cell trophism by diﬀusion,
modulate their metabolic microenvironment, and, therefore,
play a key role in tumor growth and metastasis.
4 . 2 .T h eA d o p t i o no faL e u k o c y t i cP h e n o t y p eb yC a n c e rC e l l s .
The cancer cell could express a leukocytic phenotype with
anaerobic glycolysis as the main source of energy, which
permits lymphatic migration and invasion of the host [44–
46].
Hypoxic tumor cells may suﬀer oxidative and nitrosative
stress, like what occurs to leukocytes in the chronic inﬂam-
matory response by the generation of reactive oxygen and
nitrogen species. Increased oxidative damage levels in malig-
nant cells could result from more reactive species forma-
tion with unaltered antioxidant defenses, unaltered reactive
species formation with decreases in antioxidant defenses,
failure to repair oxidative damage, so that levels rise, or any
combination of the above [71]. Overall, evidence supports
the view that at least some malignant cells produce more
reactive species for its own beneﬁt, and the antioxidant
defense and repair activities may sometimes rise, but not
enough to cope with the extrareactive species [71].
In most inﬂammatory responses, the actions of reactive
species are mediated by the IκB kinase/nuclear factor (NF)-
κB (IKK/NF-κB) system, and in turn, this system can be
regulated by hypoxia and/or reoxygenation [52, 72]. More
speciﬁcally, the expression of inducible genes leading to the
synthesis of cytokines, chemokines, chemokine receptors,
adhesion molecules, and autacoids relies on transcription
factors, and among the primary transcription factors, NF-κB
plays a main role in the regulation of inﬂammatory media-
tors [73]. In addition, reactive oxygen and nitrogen species
generated by both oncogene-expressing cells and inﬂamma-
tory cells could cause oxidative damage to host DNA result-
ing in activation of oncogenes and/or inactivation of tumor
suppressor genes and various epigenetic changes that favor
tumor progression [72].
The activated IKK/NF-κB pathway may play a tumor-
promoting role by protecting tumor cells from death, that
is,antiapoptotic, orenhancingtheirproliferation[72].How-
ever, although much attention regarding NF-κB has focused
on inﬂammatory responses and tumor development, the
current upsurge of interest in stem cell biology has led to
studies of the function of NF-κB in stem cells of the bone
marrow. NF-κB has been suggested to regulate secretion of
growth factors and cytokines in adult and neonatal stem cells
from the bone marrow environment [74].
Tumors in their development share an array of inﬂam-
matory activation mechanisms with leukocytes, including
toll-like receptors (TLRs) [32, 75], prostaglandin and leuko-
trienes’ metabolism [76], mitogen-activated protein kinasesJournal of Oncology 7
(MAPKs), that is, extracellular signal-regulated kinases
(ERKs), c-Jun NH2-terminal kinases (JNKs) and p38 iso-
forms (p38s) [77], deregulation of phosphoinositide 3-
kinase (PCI3K)/phosphatase and tensin homolog (PTEN)/
Aktpathway[78],inﬁltratingtumor-associatedmacrophages
(TAMs) [31] and lymphocytes T and B [34]a n dm i c r o R N A
expression [36].
The activation of a leukocytic phenotype by the tumor
cells could imply their transition to a more elaborated in-
ﬂammatory response. Hence, tumor cells may usurp key
mechanisms by which inﬂammation interfaces with cancer
to further their colonization of the host [46].
Theassociationbetweeninﬂammationandcancercanbe
establishedbystudyingtheinﬂuenceofinﬂammatorycellsin
tumor progression, including neutrophils, eosinophils, ma-
crophages, myeloid-derived suppressor cells, mast cells, and
lymphocytes [1, 31, 35]. However, opposing eﬀects of in-
ﬂammation on cancer have been described, and, at the risk
of oversimplifying for the sake of clarity, it can be said that
acute inﬂammation counteracts while chronic inﬂammation
promotes cancer development [79, 80]. Nevertheless, such
a link may not be as simple as the one currently portrayed
becausecertaintypesofinﬂammatoryprocessesinskin,such
as psoriasis or atopic dermatitis, and possibly other tissues as
well, may also serve as a tumor suppressor function [81].
Chronic inﬂammation is involved in shaping the tumor
microenvironment and has been referred to as “host reac-
tion,” although it might be more appropriate to think of it
as “tumor promoting” reaction [31]. In this way, cancer cells
could reconvert the inﬂammatory host response to obtain an
immunosuppressive inﬂammatory microenvironment and
thus may escape from the host aggression [1, 31, 82]. An
upregulation of immune tolerance by cancer cell could be
induced using adaptive immunity [31, 34, 82, 83]. On the
contrary, an inﬂammatory host response that switches the
nature of the tumor promoting an immunosuppressive mi-
croenvironment could kill tumor cells and produce cancer
regression [31, 82, 84].
Independently of the action of host leukocytes, and
owing to the great plasticity of malignant cells, we could sus-
pect that among the wide variety of phenotypes that they
could express, it has been shown that tumor cells co-opt
some of the signaling molecules of the host innate immune
system, like chemokines, selectins, and their receptors, for
invasion, migration, and metastasis [84]. Inﬂammation-
associated products can also be secreted by the tumor cells
themselves, giving rise to tumor microenvironment, which
is overloaded and enriched with inﬂammatory factors with
marked immunosuppressive abilities [80, 85]. In addition,
immunecellsinthetumormicroenvironmentnotonlyfailto
exercise antitumor eﬀector functions, but also are co-opted
to promote tumor growth and metastasis [31, 86]( Figure 3).
The hypothetical activation by chemokines of the leuko-
cytic phenotype in the tumor cells could permit these cells
to fulﬁll functions characteristic of activated inﬂammatory
cells. For example, functions associated with neutrophils,
such as the hyperproduction of extracellular proteases, in-
cluding MMPs and other protease enzymes that carry out a
true extracellular digestion of the basement membrane and
the extracellular matrix, also aid invasiveness in the early
stages of the disease [55, 87]. The extracellular matrix is a
reservoir for many molecules, including growth factors, and
cytokines, which are only released upon their dissolution
[88]. Also, cancer cells can present pseudopodia formation
and directional migration [89]. Other functions seem to cor-
respond to a monocyte-macrophage phenotype in the sense
thattumorcellsmigratetotheregionallymphnodesthrough
the lymphatic capillaries [69, 90]. Moreover, the so-called
fusion theory explains that the acquisition of the metastatic
phenotype occurs when a healthy migratory leukocyte fuses
with a primary tumor cell. And interestingly enough, the
fusion of genetic and cytoplasmic material between cells of
diﬀerentoriginsisanimportantphysiologicalprocessduring
development [91].
Cancer cells dissociated from the primary tumor could
change their phenotype to become more autonomous, ex-
press speciﬁc adhesion molecules, produce lymphangiogenic
factors and eventually evade the host defense [68]. The hy-
pothetical adoption of a leukocytic phenotype by most
tumor cells would also imply the acquisition of a similar me-
tabolism. In this situation, like the activated leukocytes,
cancer cells function would require glycolysis as the main
source to obtain substrates and energy [92]. In this sense, the
metabolic regulation of cancer metastatic cells could be
closely related to a speciﬁc mutational activation of onco-
genes and inactivation of tumor suppressor genes [93]. In
contrast to normal cells, cancer cells tend to convert glucose
into lactate even in the presence of suﬃcient oxygen, a
term called “the Warburg eﬀect” or aerobic glycolysis [94].
Glutamine is also a major cancer cell energy and anabolic
substrate [93]. The oncogenes, Akt, Myc, and Ras, MAP-
kinase, PI3K, and mammalian target of rapamycin (mTOR)
pathways, and HIF can stimulate the transcription of a
number of genes that encode the proteins that mediate the
glycolysis and glutaminolysis pathways [93, 94]. This
metabolic characteristic of the tumor cell in this stage would
explain why tumors grow in the lymph node, regardless of
their angiogenic ability [95]. In turn, nutrition of cancer
cells during the expression of a leukocytic phenotype could
also be based on extracellular, that is, proteolytic enzymes,
and intracellular, that is, phagocytic, functions including
autophagy and digestion [44, 45].
During the adoption of a leukocytic phenotype, soluble
factors could push tumor cells towards premature migration
to peripheral tissue [45]. Considerable progress has been
madeinrecentyearsregardinghowtumorcellscirculatingin
thebloodandlymphaticsysteminteractwithandextravasate
into secondary sites and what determines whether these dis-
seminated tumor cells survive, remain dormant, or go on
to form macrometastases [96]. Hence, the leukocytic phe-
notype would favor the homing of metastatic tumor cells to
speciﬁc organs, especially those where populations of res-
ident macrophages are abundant, that is, lung (alveolar
macrophages), liver (Kupﬀer cells), brain (glia), and bone
(osteoclasts)[44].Particularly,speciﬁcchemokinesindistant
organs and chemokine receptors on the tumor cells dictate a
metastasis pattern according to the cancer cells [97].8 Journal of Oncology
Tumor-cell-derived factors, which could also be partially
contributed by tumor-inﬁltrating macrophages [31], have
been found to induce the expansion of the lymphatic net-
work in the lymph nodes, even before the arrival of the
metastaticcancercells,asiftocreateafavorableenvironment
for the future metastasis [98, 99]. Also, disseminated tumor
cells in bone marrow can be detected in 20–40% of cancer
patients without any clinical or histopathological signs of
metastasis [100]. The particular bone marrow environment
may induce these cells to survive and disseminate later into
other distant organs. This “dormant stage” of disseminated
tumorcellsmayexplainwhythesecellsarerelativelyresistant
to chemotherapy [101].
The adoption of a leukocytic phenotype by cancerous
cells could be associated with an increased degree of lym-
phangiogenesis. In animal models, a strong relationship be-
tween lymphangiogenesis and survival has been shown [67].
Lymphangiogenesis at the site of the primary tumor as well
as in the draining lymph node actively contributes to meta-
static cancer spread, and its inhibition might be of interest
for preventing tumor metastasis [67, 98, 102]. Lymphangio-
genesis not only is crucial for cancer cells to metastasize, but
also oﬀers the tumor the possibility to disseminate inﬂam-
matory mediators in the host, which would produce a sys-
temic inﬂammatory response syndrome (SIRS) [45, 103].
The SIRS, mediated in part by proinﬂammatory mediators
including cytokines, plays a role in the genesis of cachexia
associated with both critical illness and chronic inﬂamma-
tory diseases [104]. The systemic inﬂammatory and immune
response to the presence of a tumor is manifested in diﬀerent
ways, according to the type and extent of the tumor. Fever,
night sweats, weight loss, fatigue and malnutrition may all
be attributable to tumor-induced inﬂammation [3]. Cancer
cachexia is a continuum with three stages of clinical rel-
evance: precachexia, cachexia, and refractory cachexia, but
not all patients traverse the entire spectrum [105]. Addi-
tionally, although an acute phase protein response is usually
produced, the C-reactive protein in serum is the most widely
accepted index of systemic inﬂammation, and cachexia can
be present in the absence of overt systemic inﬂammation
[105]. Thus, the host, as a yolk-sac-like structure, becomes
a vitellum supplier for the tumor growth.
The tumor cell, through the lymphatic system, can also
modulate the host immunity, using its own antigen produc-
tion. Tumoral antigens in the interstitial ﬂuid are collected
into open-ended lymphatic capillaries, which can form a
mesh-like network by lymphangiogenesis, which could then
be transported to the lymph nodes [106]. However, tumoral
antigens in prenodal lymph, before entering the node and
once inside, could be ﬁltered by dendritic cells and nodal
antigen-presenting cells, respectively [106]. Thus, lymph-
carried tumoral antigens might have particular relevance for
the induction and maintenance of peripheral tolerance to
cancer cells.
The functional plasticity of dendritic cells allows for
adapting the immune system to mount functionally distinct
typesofresponses,includingtheimmunologictolerancethat
couldcontributetotumordevelopment[82].I nthiswa y ,itis
acceptedthatdendriticcellvaccineswillbeoﬀeredtopatients
either with early- or late-stage disease to elicit a strong and
long-lived antigen-speciﬁc T-cell immunity [82].
Additionally, lymphatic vessel density can increase in the
chronic inﬂamed tumor tissue, although without reestab-
lishing an eﬃcient lymphatic connection with the draining
lymph nodes [107]. This defective lymphatic drainage, asso-
ciated with the enduring local tumoral antigen stimulation,
could be a crucial trigger of the cascade of events leading to
lymphoid neogenesis [108]. De novo lymphoid tissue for-
mation or tertiary lymphoid organs occur during states of
chronic inﬂammation [69]. Tertiary lymphoid organs may
accumulate tumor antigens and tumor antigen-presenting
cells, bypassing the lymph node function and therefore cir-
cumventing their tolerance-maintaining function [69, 108].
In addition, myeloid-derived suppressor cells, a heterogenic
population of immature myeloid cells that consists of my-
eloid progenitors and precursors of macrophages, granu-
locytes, and dendritic cells, use a number of mechanisms
to suppress various T-cell functions as well as to induct
regulatory T-cells [109].
4.3.Granulation-Tissue-Related CancerCells. Cancer cells,to
grow inside the host, need to induce the formation of a
stroma to change in an organ. Therefore, the comparison of
tumors with wounds that do not heal includes, among other
characteristics,thedevelopmentofastromainwhichthefor-
mation of ﬁbroblasts, through a process named ﬁbroplasia,
mainlytakesplace[6].Thisphaseofskinwoundhealing,also
called granulation phase, is basically characterized by active
ﬁbroplasia and angiogenesis [110]( Figure 3).
The role of ﬁbroblasts in wound healing has been exten-
sively studied over the past years. Fibroblasts and myoﬁbrob-
lasts mainly produce the new extracellular matrix necessary
for supporting cells and blood vessels, which provides nutri-
ents and oxygen needed for cell growth and proliferation
[110]. This new matrix consists of collagen, proteogly-
cans, and ﬁbronectins produced by the ﬁbroblasts. Fibrob-
last activity is predominantly regulated by platelet-derived
growth factor (PDGF) and transforming growth factor β
(TGFβ)[ 111]. Growth factors involved in ﬁbrogenesis also
include ﬁbroblast growth factor-2 (FGF-2) and hepatocyte
growth factor (HGF), which are also chemotactic factors for
mesenchymal stem cells. Complementary to this, it has been
demonstrated that keloid-derived ﬁbroblasts induce higher
mesenchymal stem cell migration toward themselves than
normal ﬁbroblasts [112]. Also, it must be noted that keloids
are locally aggressive scars that typically invade healthy
surrounding tissues [112]. Recent studies indicate that mes-
enchymal stem cells from the bone marrow provide “ﬁbrob-
lasts” to the skin in adults and are thought to enhance skin
repair/regeneration [33, 113].
In recent years, the tumor stroma has become the focus
ofintenseresearch.Inparticular,ﬁbroblasts,aheterogeneous
collection of mesenchymal cells, are among the most abun-
dant cell types in the microenvironment of solid tumors
[37]. Cancer-associated ﬁbroblasts, through the release of
cytokines and growth factors, could modulate the cancer
stem cell phenotype and could also lead to enhancedJournal of Oncology 9
angiogenesis [33, 37]. It has been suggested that cancer-
associated ﬁbroblasts may be derived from tumor cells
that undergo epithelial-mesenchymal transition [114]. One
characteristic of the cancer-associated ﬁbroblasts is their
heterogeneity, which is also expressed through the formation
in solid tumors of a very diﬀerent proﬁle of extracellular
matrix proteins [37]. Mesenchymal stromal cells also can
suppress immune responses, favoring tumor cells’ escape
from the host immune response [115].
Angiogenesis characterizes a phase of cancer evolution
that permits numerous substances, including hormones, to
be transported by the blood. Angiogenesis requires migra-
tion of endothelial cells into the interstitial space with the
subsequent proliferation and diﬀerentiation into capillaries
[44]. Tumors induce angiogenesis by activating tumor stro-
mal cells. The release of angiogenic factors from the extracel-
lular matrix through new formed epitopes promotes angio-
genesis. Thus, the neoplastic cells switch to an angiogenic
phenotype [116]. However, tumor angiogenesis produces a
tumor-associated vasculature that is chaotic, both in struc-
ture and function. Although angiogenesis supplies a growing
tumor with nutrients and oxygen, the neo-vasculature is
poorly formed often with leaky blood vessels that do not link
the arterial to the venous circulation but is rather dead-end
[42, 117]. This characteristic impairs tumor blood ﬂow and
thedeliveringofoxygen[118],buttheyfavoritsgrowthsince
without angiogenesis tumors rarely grow to larger than 2 to
3mm [119]. However, the tumor during its growth seems
to prioritize the venous-lymphatic circulation in detriment
of the arteriovenous circulation, which is characteristic of
the specialized tissues. This circulatory switch perhaps could
oﬀer some metabolic advantages to the tumor biology; for
instance, it would favor an environment poor in oxygen,
strengthening therefore an eﬃcient anaerobic metabolism
that forms biomass, and to the blood endothelium with an
inﬂammatoryphenotype; it wouldgive morepermeability to
molecules and cells and it would also enrich the composition
of the interstitial space. In essence, a “reactive stroma” would
be created [59, 120]. The normal stroma in most organs
contains a minimal number of ﬁbroblasts, whereas a reactive
tumor stroma could be associated with an increased number
of cells, including ﬁbroblasts, enhanced vessel density, and
protein deposition [59].
Cancer cells are also associated with high endothelial
venule development. Lymphocytes get into lymph nodes
from the blood through high endothelial venules. T and
B cells subsequentlymove into the T zone and B-cell follicles,
respectively, and then migrate in a stromal-guided random
walk [121]. In contrast to the ﬂat endothelial cells that
line other types of blood vessels, high endothelial venule
endothelial cells are almost cuboidal, and they selectively
express certain tissue-speciﬁc adhesion molecules and che-
mokines [122]. High endothelial venules are mainly found
in the paracortical and interfollicular areas of the lymph
node and are surrounded by an intricate stromal network
consisting of ﬁbroblastic reticular cells. However, high-
endothelial venule-like structures are also associated with
tertiary lymphoid organs, which represent highly orga-
nized lymphoid tissues induced by inﬂammation [122]. In
addition, recruitment of lymphocytes and dendritic cells to
inﬂamed lymph nodes by trans-high-endothelial venule mi-
gration involves the mediation of heparan sulfate [123].
Tumors build their blood vessels by mechanisms that
involve endothelial cell response, including circulating endo-
thelial precursors and circulating endothelial cells, to tumor
signaling[97].Recentworksprovideevidenceindicatingthat
the state of endothelial cell activation in the tumoral niche,
rather than angiogenesis itself, may dictate tumor dormancy
or escape. In essence, the crosstalk between tumor cells and
stromal cells, including endothelial cells within the tumor
microenvironment, mediates tumor evolution [97, 124].
Within the factors that play a role in initiating tumoral
neovascularization, the “classical,” that is, VEGF, ﬁbroblast
growth factor-2 (FGF-2), also termed basic ﬁbroblast growth
factor (bFGF), platelet-derived growth factor (PDGF), trans-
forming growth factors (TGFs), and angiopoietins (Angs),
and the “nonclassical” mediators of angiogenesis, that is,
erythropoietin, angiotensin II, endothelins, and thyroid
hormones, stand out [125].
However, as it has been previously explained, tumor vas-
culature is typically aberrant [117] with a reduced pericyte
coverage, which in turn destabilizes vascular integrity and
function [126]. Additionally, vascular heterogeneity could
be associated with subpopulations of cancer cells that dif-
fer in their energy-generating pathways, macromolecular
biosynthesis, and redox control [42, 43, 126, 127]. These
populations may function symbiotically since the cells proxi-
mal to a better-oxygenated tumoral tissue consume oxygen
with glucose and glutamine, serving as substrates and se-
creting lactate that can be used by another subpopulation of
hypoxic cancer cells as their main energy source [42, 126].
In a similar compensatory way, the activation of HIF in the
hypoxic cancer cell subpopulation or in stromal cells within
the tumor could augment their vascularization and oxy-
genation. This change could be associated in turn with
tumoral blood ﬂow redistribution, rendering other areas of
the tumor ischemic, and consequently with a hypoxic me-
tabolism that induces an increase in tumor invasiveness
and risk of metastasis [50]. Thus, it can be suspected that
the metabolic and functional heterogeneity of the tumors,
which is imposed by their stroma, that is, granulation tissue-
like, is dynamic. This tumoral dynamic heterogeneity could
constitute a favoring factor of chronicity.
5. Inﬂammatory Cancer Phenotypesand
RelatedMetabolisms:RegardingtheNeed
for a Metabolic Stagingof Cancer
Given the hypothetical plasticity of malignant tumor cells,
the above-mentioned inﬂammatory phenotypes would need
the corresponding metabolic plasticity. Hence, the mecha-
nisms that govern tumoral evolution could be based on the
increasing metabolic capacity of the tumor cell to use oxygen
over the inﬂammatory phenotypes that supposedly drive
the successive phases of release, migration, and proliferation
[44–46]. Since it has been proposed that these phases of10 Journal of Oncology
tumoral evolution go from hypoxia to the progressive devel-
opment of an oxidative metabolism, it has been speculated
on whether the tumor cell reproduces most of the successive
stages by which life passes [44] from its origin without
oxygen until it develops an eﬀective, although costly, system
for the use of oxygen [128]. If so, in the successive metabolic
switches that cancer undergoes, it acquires an increasing
ability to both invade the host and use its sources of
substratesuntilitsmetabolicreservesareallusedup[44,45].
The ability of cancer cells to change their metabolism
and, therefore, their inﬂammatory phenotypes is one of the
fundamental reasons why metabonomics oﬀers a platform
for biomarker development in the ﬁeld of oncology [129].
Yet cancer metabolism represents an ideal ﬁeld for metabolic
proﬁling because of the way its metabolism diﬀers metab-
olism from normal cells, especially that of the glucose and
phospholipid [130]. Tumoral metabolic proﬁling, not only
could allow us to study each tumoral inﬂammatory phe-
notypebutwouldalsooﬀerthechanceofcorrelatingtumoral
metabolism with its invasiveness to the host.
The hypoxic phenotype would characterize the initial
step of tumoral evolution. In this early phase of the cancer
cell response, it could be considered that hypometabolism,
anaerobic glycolysis with lactate production, and a low ener-
gy expenditure [131] could be related to a primitive cellular
trophic mechanism, like diﬀusion. [44, 45]. In this supposed
state of cancer cell stunning, complex or specialized func-
tions could not be expressed. It is conceivable that near-
anoxic cancer cells initiate a transcriptional response that
compensatesthelowmetabolicdemandwithreducedoxygen
availability. The key player of this adaptive response is HIF
[132–134]. However, the HIF complex modulates signaling
by Notch, a critical regulator of undiﬀerentiated stem and
progenitor cells [134].
TheNotchsignalpathwayisinvolvedincellfatedecisions
during normal development but also in the genesis of several
cancers [135, 136]. Activation of Notch leads to prote-
olytic cleavage of the intracellular domain of Notch. Thus,
translocation of Notch intracellular domain into the nucleus
induces the transcriptional activation of Notch target genes
[135, 137]. Notch target genes include proteins and factors
involved in the control of the cell cycle and survival processes
[137, 138]. In human cancers, activation of Notch signaling
also can establish crosstalks with many oncogenic signaling
pathways, such as developmental signals, for example, Wnt
and Hedgehog signaling [138]. In particular Hedgehog plays
a key role in a variety of processes such as inﬂammation,
carcinogenesis, and embryogenesis [137, 138].The signaling
pathways that control self-renewal of stem cells are an es-
sential element for tumor survival. That is why cancer stem
cells use many of the above-mentioned signaling pathways
that are found in normal stem cells, such as Wnt, Notch, and
Hedgehog [137, 139].
Tumor metabolism related to the leukocytic phenotype
could be able to manage the increased oxidative and nitrosa-
tive stress and hypermetabolism imposed by reoxygenation.
Recently, the presence and generation of reactive oxygen
species attracted increased interest as a microenvironmental
factoraspartofreoxygenationaﬀectingthesurvivaloftumor
cells [140]. In particular, upon reoxygenation, hypoxic cells
could experience apoptosis, but there is also evidence that
malignant cells can increase their tolerance in response to
adverse metabolic conditions [127, 140]. In turn, metabolic
stress situations, such as oxidative stress, low pH, or low
glucose, are likely to be major determinants of the metabolic
phenotype. The regulation of this “metabolic ﬂexibility” is
poorly understood and will require a much greater degree
of understanding if eﬀective therapeutic strategies targeting
metabolism are to be developed and eﬀectively deployed
[127].
The pentose phosphate cycle is composed of two branch-
es: the irreversible oxidative pentose pathway that converts
glucose-6-phosphate to ribose phosphates thereby yielding
two moles, NADPH H+, per mole glucose, and the nonox-
idative pentose phosphate pathway that reversibly converts
three pentose phosphates into two hexose phosphates, for
example, fructose-6-phosphate, and one triosephosphate
[131, 141]. The normal cells produce most of the ribose-
5-phosphate for nucleotide synthesis through the oxidative
pentose pathway; however, in tumor cells, the nonoxidative
pentose phosphate pathway is the main source for ribose-
5-phosphate synthesis. In turn, it is accepted that there are
major diﬀerences in the relative share of these two pathways
in the delivery of pentose phosphates when comparing slow
and fast-growing carcinoma [131].
In particular, in response to oxidative-stress, central car-
bohydrate metabolism could be reconﬁgured, so that the
metabolic ﬂux reroutes from glycolysis into the pentose
phosphate pathway, which allows cells to mount an eﬀective
response to this cellular stress [142, 143]. Activation of the
pentosepathwayalsocouldcontributetomanyoftheunique
metabolic requirements of tumor cells. Through its gener-
ation of NADPH, the oxidative arm of the pentose phos-
phate pathway provides reducing power to drive anabolic
metabolism [143]. If so, deﬁciency of the pentose phosphate
pathway could inﬂuence the development of a diverse variety
of oxidative stress-associated human diseases, ranging from
autoimmune diseases to carcinogenesis [144].
The mammalian target of rapamycin (mTOR) is an ev-
olutionary conserved Ser/Thr kinase, which could play a
major role in the metabolic reprogramming of tumor cells
[143, 145]. In addition to its well-known roles in promoting
protein synthesis and inhibiting autophagy [43], mTORC1
has been found to stimulate glucose uptake, its conversion
to glucose 6-phosphate, and metabolic ﬂux through both
glycolysis and the oxidative arm of the pentose phosphate
pathway [143]. As mTORC1 signaling is aberrantly elevated
in the majority of genetic tumor syndromes and sporadic
cancers, this pathway is poised to be a major driver of this
metabolic conversion of tumor cells [146].
Notch-mediated signals can upregulate several factors
that in turn transmit bidirectional signals among cancer cells
expressing both ligands and receptors. Therefore, it is not
surprising that Notch signal crosstalks with many oncogenic
signaling pathways, such as developmental signals including
Wnt and Hegdehog, as well as transcriptional factors, for
example, NF-κB[ 138]. In particular, IL-1 activates Notch
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pathway is also a critical downstream target of IL-6 [138].
It has been accepted that the family of NF-κB transcription
factors is involved in the expression of genes related to innate
and adaptive immunity, which suggests that this signaling
pathway could also favor the expression of the leukocytic
phenotype in cancer cells. Therefore, Notch signaling could
also be required to convert the hypoxic stimulus into epithe-
lial-mesenchymal transition favoring the motility and inva-
siveness of cancer cells [140, 147].
Finally, sonic hedgehog (Shh), a member of the Hedge-
hog family, is involved in numerous aspects of embryonic
development including angiogenesis and lymphangiogenesis
[148]. Shh is an established morphogen critical to the de-
velopment of the vascular system, but in adult ischemic
pathologies, it stimulates the production of angiogenic fac-
tors, including VEGF-A and angiopoietin-1. It also promotes
endothelialcellchemotaxis[148,149].Intheischemiccancer
cell,ShhactingconcomitantlywiththeNotchsignalingpath-
waycouldalsostimulatetheproductionofangiogenicfactors
[135, 137, 149]. These newly characterized pathways have
been functionally implicated in the development and tumor-
associated angiogenesis. They also illustrate the complex
regulation of endothelial cell phenotypes [126]. As a result, a
broader concept of the tumoral angiogenic process is needed
for its better study and for a better comprehension of the
involved mechanisms since both blood and lymphatic vessels
are major vascular components of the tumor. This is the
reason why the tumor-associated blood/lymph angiogenesis
isacceptedasaprocessinducedbycomplicatedcytokinenet-
works, mediated by the paracrine and autocrine interactions
between tumor cells and stromal cells [150].
Thus, tumor nutrition mediated by blood and lymphatic
capillaries could be established thanks to angiogenesis. The
new functional properties of tumor microcirculation could
include the exchange of oxygen, nutrients, and waste pro-
ducts [44, 45] and favor tumor growth, invasion, and me-
tastasis [151, 152]. Recent information on mitochondrial
metabolism in malignant neoplasia emphasizes that, al-
though tumor cells maintain a high glycolytic rate, the prin-
cipal ATP production may be derived from active oxidative
phosphorylation [153]. The result of these metabolic charac-
teristics is that tumors burn glucose while consuming muscle
protein and lipid stores of the organism. As a result, tumor
metabolism gives them a selective advantage over normal
cells [154].
6.CancerCellMeetsAmnioticandVitelline
Functional Axes
The concept that cancer and embryonic cells have much
in common is an old idea. The morphological resemblance
between cancer cells and the cells of fetal tissues has been
repeatedly discussed in current biomedical literature [155]
(Table 3). In the mid-19th century, upon observing cancer
tissue under the microscope, the forefathers in pathology
noticed the similarities between embryonic tissue and cancer
andsuggestedthattumorsarisefromembryo-likecells[156].
More recently, it became clear that neoplastic cells possess a
more embryonic phenotype than their tissue of origin and
that this involves the expression (or reexpression) of embry-
onic genes [157]. Both embryos and tumors display similar
antigens, elaborate angiogenic growth factors, and sub-
vert apoptotic cell death. Furthermore, they may both escape
immune destruction by similar mechanisms [157].
Recentstudieshaveshownthatitispossibletoreprogram
the melanoma tumorigenic phenotype by exposing mela-
noma cells to factors present in the embryonic microen-
vironment [158]. This suggests that melanoma cells may
share some characteristics with stem cells that allow them to
respond to the ones from the embryonic microenvironment
[159]. It became clear that neoplastic cells posses a more
embryonicphenotypethantheirtissueoforiginandthatthis
involves the re-expression of embryonic genes [157, 159].
Theconvergenceofembryonicandtumorigenicmechanisms
has indeed allowed suggesting the use of embryonic vaccines
against cancer in the past [157].
Tissue interstitium under conditions of long-lasting
inﬂammation is associated with oxidative stress, edema,
enzymatic stress, persistent leukocyte stimulation, lymphan-
giogenesis, angiogenesis, and ﬁbrosis [160, 161]. It has been
proposed that if the insult is sustained, for example, chronic
inﬂammatory response, additional proinﬂammatory media-
tors can activate a wide variety of leukocytes including ma-
crophagesandlymphocytes,whichcancontributestofurther
tissue destruction and inﬂammation [162]. However, pro-
longed inﬂammation in wounds contribute to the develop-
ment of ﬁbroproliferatiove scarring, in other words, keloids
and hypertrophic scars [163]. Moreover, in autoimmune
diseases, persistent antigenic stimulation recruits endoge-
nous mesenchymal stem cells to the site of the lesion that
contributes to the ﬁbrotic evolution [164].
Transforming growth factor (TGF)-β signaling in stro-
mal cells, for example, ﬁbroblasts, also exerts signiﬁcant
eﬀectsontumordevelopmentandgrowth.Ithasbeenshown
that TGF-β, an important tumor suppressor, also regulates
inﬁltration of immune cells as well as ﬁbroblasts in the
tumor microenvironment and promotes tumor progression
[165]. Fibroblasts could also produce c-Kit ligand, the most
important mast cell growth factor, while mast cells’ pro-
teases released from activated mast cells have an important
eﬀect on ﬁbroblasts [166]. There is evidence that cancer-
associated ﬁbroblasts have a cancer-promoting phenotype
[167]. Consequently, cancer-associated ﬁbroblasts could
produce signiﬁcant extracellular matrix remodeling during
tumor progression mediated by tumor-speciﬁc extracellular
matrix proteins and matrix metalloproteinases isoforms
[37].
Adult mesenchymal stem cells can be deﬁned as multi-
potent cells able to diﬀerentiate into various types including
specializedmesenchymalcells.Thebehaviorofmesenchymal
stem cells towards the immune system is context sensitive.
Although the antiﬁbrotic eﬀects of mesenchymal stem cells
have been demonstrated, the molecular mechanisms behind
this eﬀect are not yet fully understood. However, the angi-
ogenic support provided by mesenchymal stem cells is con-
sidered the more supportive eﬀect, because reestablishment
of blood supply is fundamental for the recovery of damaged
patients [168].12 Journal of Oncology
In contrast to adult wound healing, the early gestation
fetus has the remarkable ability to heal skin wounds without
scarring [169, 170]. There are numerous intrinsic and out-
rinsic diﬀerences between the fetus and adult that may inﬂu-
ence wound healing. The fetal wound is continuously bathed
in amniotic ﬂuid rich in growth factors and extracellular
matrixcomponentssuchashyaluronicacid,typeIIIcollagen,
and matrix metalloproteinases. In addition, fetal wound
healingischaracterizedbyarapidupregulationinprogenitor
cells of genes involved in cell growth and proliferation, with
decreased platelet aggregation and degranulation, compared
to adult wound healing [170].
One intrinsic diﬀerence also includes fetal tissue oxy-
genation. The fetus has a very low pO2 since there is a large
transplacentaloxygengradientbetweenmaternalarterialand
umbilical venous blood. Consequently, the fetus can heal in
a relatively hypoxemic environment [169].
Epithelialtomesenchymaltransitions(EMTs)aretransd-
iﬀerentiation programs that are also required for tissue mor-
phogenesis both during embryonic and cancer development
[171, 172]. The conversion of epithelial cells to mesenchymal
cellsisfundamentalforembryonicdevelopmentandinvolves
profound phenotypic changes, including the loss of cell-cell
adhesionandtheacquisitionofmigratoryandinvasiveprop-
erties [114, 171]. Recent evidence suggests that normal stem
cells and cancer stem cells share a mesenchymal phenotype
that enhances their ability to preserve stemness, to retain
migratory properties, and to respond to diﬀerent stimuli
during expansion and diﬀerentiation [171]. Thus, EMT in-
duction in cancer cells results in the acquisition of invasive
and metastatic properties [171, 172]. Interestingly enough,
these invasive cells, with both a stem-cell-like and mesenchy-
mal phenotype, can generate an epithelial-like structure by
mesenchymal to epithelial transition (MET) and, therefore,
couldbeinvolvedintheformationofmacrometastasis[171].
Furthermore, it is accepted today that metastasis progression
should be considered an independent and parallel process
in tumorigenesis governed by the EMT that occurs among
tumorcells[91,114,172].Inaddition,althoughthemajority
of tumors are epithelial, they also exert mesenchymal
characteristics [91, 171, 172].
An EMT process also occurs in mammalian embryos
during gastrulation [114]. Gastrulation is a developmental
phase that delineates the three embryogenic germ layers,
namedectoderm,endoderm,andmesoderm.Haeckelcoined
the term gastrulation derived from the Greek word “gaste,”
meaning stomach or gut, that transforms the rather unstruc-
tured early embryo into a gastrula with several speciﬁc char-
acteristics: the three primary germ layers are formed; the
basic body plan is established, including the construction of
the rudimentary body axes; the cells assume new positions,
allowing them to interact with cells that were initially not
closetothem[173].Thenascentmesodermgeneratedduring
gastrulation could involve an internalization process of ex-
traembryonic phenotypes [114]. In essence, gastrulation
could be represented as the creation of an interstitial space
in which extraembryonic, that is, amniotic and vitelline,
functions are expressed using mesenchymal cells. If so, the
mesoderm would represent the vehicle or the mediator for
the internalization of the extraembryonic functions into the
embryos [8]( Figure 1).
The mesenchymal state is associated with the capacity
of cells to migrate to distant organs and maintain stemness
allowing their subsequent diﬀerentiation into multiple cell
types during development and the initiation of metastasis
[114, 171]. In amniotes, members of the TGF-β superfamily
induce gastrulation and Nodal signaling together with
ﬁbroblast growth factor (FGF) and control the speciﬁcation
of the mesendoderm in all vertebrates [171]. Mesenchymal
stem cells are a heterogeneous population with several sub-
groups of cells with diﬀerent proliferative and differentiation
potentials [9]. Mesenchymal stem cells support hematopoie-
sis and are able to diﬀerentiate towards the mesodermal lin-
eage to generate smooth muscle cells, ﬁbroblasts, pericytes,
myoﬁbroblasts, osteoblasts, chondrocytes, and adipocytes
[9].
Hypoxia is commonly associated with conditions such as
tissue ischemia, inﬂammation, and solid tumors. However,
hypoxic niches in the developing embryo are associated with
regulation of cellular diﬀerentiation [174]. In this sense,
mammalian development occurs in a relatively oxygen-poor
environmentandbeforethecirculatorysystemisestablished.
Therefore, it would seem logical that blood vessel patterning
could be ﬁne-tuned by local hypoxic microenvironments
that are encountered during embryogenesis, organogenesis,
and tumorigenesis [174]. This is why it could be considered
thathypoxiacouldinﬂuencethebehaviorofcancerstemcells
and their progeny promoting a defective tumor angiogenesis
with vascular-like networks [159].
Fibroblastsareamongthemostabundantcelltypesinthe
microenvironment of solid tumors. Carcinoma-associated
ﬁbroblasts promote tumor growth and invasion and stim-
ulate angiogenesis [37]. However, the altered phenotype of
carcinoma-associated ﬁbroblasts with the production of an
impaired extracellular matrix and favoring the interstitial
inﬁltration by inﬂammatory cells [37]c o u l db ek e yf a c t o r s
for inhibiting the diﬀerentiation of the tumoral microcir-
culation. In turn, this immature microcirculation would be
responsible for the tumor-uncoupled metabolic functions
regarding the normal microcirculation, as well as its prolif-
erative ability and invasiveness of the host.
The vast arrangement of the mesenchyma around and
between the developing amniotic and yolk sac cavities sug-
gests an important role of the mesenchyma in orchestrating
embryodevelopment.Mesenchymaisolatedspeciﬁcallyfrom
the amniotic membrane could diﬀerentiate into neuronal-
like cells which are identiﬁed to secrete dopamine [175].
Cells derived from amniotic ﬂuid also have a neuronal, do-
paminergic phenotype [176]. These results allow for con-
sidering the amnion as an embryonic functional axis with
strong neural potential [175, 176]. In addition, experimen-
tal and clinical studies have demonstrated that amniotic
membrane transplantation has important biological proper-
ties,includinganti-inﬂammatory,antimicrobial,antiﬁbrosis,
and antiscarring, as well as low immunogenicity [177,
178]. Amnion-derived multipotent progenitor cells secrete
a unique combination of cytokines and growth factors,
knownas“amnion-derivedcellularcytokinesolution,”whichJournal of Oncology 13
establish a communication network between mesenchymal
and epithelial cells during embryo development. That is why
using the amnion to accelerate wound healing through its
functions has been proposed, which regulates migration,
proliferation, and diﬀerentiation of ﬁbroblasts as well as of
keratinocytes [179].
Inturn,theextraembryonicvisceralyolksacinmammals
is composed of two layers, that is, the visceral endoderm,
which is active in endocytosis/digestion and has large ly-
sosomes, and the underlying mesoderm layer [180]. In the
embryonic mesoderm layer, “blood islands” develop sup-
porting hematopoiesis and angiogenesis [181]. While for-
mation of the various primitive hematopoietic populations
is restricted to the yolk sac, progenitors of deﬁnitive hem-
atopoietic cells that arise in the yolk sac may contribute to
hematopoiesis in the embryo proper [181]. Also, a major
function of the yolk sac is associated with the accumulation
of carbohydrates, proteins, and lipids for embryo nutrition
(vitellum)[ 16]. Particularly, the yolk sac plays a vital role
in providing lipids and lipid-soluble nutrients to embryos
during the early phases of development [16]. Interstitial lipid
accumulation of cholesterol, a precursor molecule of many
hormones, like aldosterone, corticoids, androgens, strogens,
and progesterone, may favor ﬂuid inﬁltration and cell mi-
gration, proliferation, and diﬀerentiation during embryo de-
velopment [19].
Dissecting out the possible contribution of extraembry-
onic lineagesto the embryo proper hasbeen diﬃcult, inlarge
part because of the inaccessibility of the mammalian embryo
within the uterus [181]. In addition, the term “extraem-
bryonic” is somewhat a misnomer, as there is no clear ana-
tomical or molecular demarcation to separate the embryonic
from the extraembryonic tissues during the early steps of
the development. Also, at later stages both are integral com-
ponents of the developing embryo [182]. However, recent
studies suggest that extraembryonically derived functions
and cells make an increasingly signiﬁcant and possibly exclu-
sive contribution to the embryonic development [44, 181].
Thus, the molecular and cellular contribution made by both
extraembryonic structures, that is, the amnion and the yolk
sac, to the interstitial space located between them, namely,
the mesoderm, are essential for organogenesis. Particularly,
both in the amnion axis and in the yolk sac axis, the ex-
traembryonic mesenchyma plays an important role [9].
The internalization of extraembryonic functions, that is,
amniotic-like and vitelline-like, by mesenchymal cells not
only could be a key process of the embryonic development,
but also could be used by the postnatal organism when it
suﬀers an injury and, therefore, needs to be repaired. Thus,
an acute or chronic injury could induce a dediﬀerentiation
process with the expression of diﬀerent and overlapping in-
ﬂammatory phenotypes that resemble similar phenotypes
expressed during embryo development. Particularly, molec-
ular and cellular amniotic and vitelline mechanisms involved
in gastrulation would return [8].
Moreover, the relationship between inﬂammation and
cancer also could be based on the orchestration of extraem-
bryonic functions. If so, tumorigenic cancer cells could suc-
cessively induce the expression of overlapping amniotic and
Table 2: Hypothesized cancer cell extraembryonic (amniotic and
vitelline) and embryonic (gastrulation) phenotypes.
(i) Amniotic-like phenotype
(a) Abnormal ion transport
(b) Extracellular matrix permeability
(c) Diﬀusion
(d) Increased interstitial ﬂuid (cytokines-substrates)
(e) Interstitial-lymphatic axis
(f) Circulatory switch
(g) Stem cancer cell
(ii) Vitelline-like phenotype
(a) Fat transport
(1) Lipoproteins
(2) Cholesterol
(b) Hematopoiesis
( 1 )B o n em a r r o wc o n t r o l
(2) Platelets
(3) Neutrophils
(4) Mast cells
(5) Tumor-associated macrophages
(6) Lymphocytes
(7) Dendritic cells
(c) Lymphatic metastasis
(d) Immunotolerance
(e) Angiogenic switch
(f) Cachexia
(1) Using the host as vitellum
(iii) Gastrulation–like phenotype
(a) Tumoral stroma
(1) Epithelial-mesenchymal transition
(2) Granulation tissue
(b) Tumoral parenchyma
(1) Mesenchymal epithelial transition
(2) Tumor growth
(c) Tumoral organ
(1) Tumoral tissue heterogeneity
vitelline-like phenotypes that promote the invasion, con-
trol, and remodeling of the interstitium. The amniotic-like
phenotype could oﬀer the cancer cells an interstitial-lym-
phatic axis [59], favoring transport, nutrition by diﬀusion,
excretion, and bacteriostatic and anti-inﬂammatory protec-
tion [179]. In turn, the vitelline phenotype could favor the
regulation of lipid metabolism genes, including cholesterol
and eicosanoid homeostasis [76], hematopoietic/bone mar-
row control [113], and the induction of an “angiogenic
switch” [117, 126] to permit tumor and metastatic growth.
The integration of both extraembryonic phenotypes by the
cancer cell would support the functional and metabolic het-
erogeneity needed to successively modulate their microenvi-
ronment during their development in the host (Table 2).14 Journal of Oncology
Table 3: Common metabolic and functional characteristics of the
embryonic and the cancerous axis under hypoxia.
(i) Avascular stage of development
(ii) Notch-signaling pathway
(iii) Hedgehog-signaling pathway
(iv) Mammalian target of rapamycin (mTOR)
(v) Prolyl hydroxylase (PHD)-hypoxia-inducible transcription
factor (HIF) system
(vi) Aerobic glycolysis (“Warburg eﬀect”)
(vii) Oxidative and nitrosative stress
(viii) Antioxidant defenses: glutamine metabolism, oxidative and
nonoxidative pentose phosphate pathways
(ix) Matrix metalloproteinases
(x) IκB kinase/nuclear factor (NF)-κB (IKK/NF-κB) system
(xi) Chemokines and adhesion molecules
(xii) Toll-like receptors
(xiii) Lymphangiogenesis
(xiv) Prostaglandins and leukotrienes active metabolism
(xv) Mitogen-activated protein kinases (MAPKs)
(xvi) Tumoral/embryonic antigens
(xvii) Lymphoid neogenesis
(xviii) Epithelial mesenchymal transition
(xix) Mesenchymal stem cells/ﬁbroblasts
(xx) Growth factors and chemotactic factors for mesenchymal
stem cells
(a) Platelet-derived growth factor (PDGF)
(b) Transforming growth factor β (TGF-β)
(c) Fibroblast growth factor-2 (FGF-2)
(d) Hepatocyte growth factor (HGF)
(xxi) Angiogenesis (“angiogenic switch”)
(a) Vascular endothelial growth factor A (VEGF-A)
(b) Angiopoietin-1
(c) Endothelial cell chemotaxis
(xxii) Selective metabolic advantage
The new point of view proposed in the current review
would be based on considering the extraembryonic mecha-
nisms as the expression of an ancient type of inﬂammatory
response. Ancestral mechanisms of natural and acquired
immunity immersed into the amniotic and vitelline axes
wouldallow the acceptation of new and foreigntissues by the
host. Therefore, the neoformed tissues, either physiological,
that is, embryo and repair tissue, or pathological, that is,
cancer, both of them being alien to the host organism, would
needtousesimilarextraembryonicmechanismstobegrafted
successfully.
The involvement of these extraembryonic mechanisms,
which are individualized in each patient in tumorigenesis,
would be a key inducing factor of the vast heterogeneity of
cancer [183, 184]. Moreover, cancer cells could be modiﬁed
through epigenetic modiﬁcations that alter gene-expression
patterns. Like all the cells that constitute the human body,
a cancer cell is a direct descendent of the fertilized egg from
which the cancer patient developed. Compared with the fer-
tilized egg, the cancer genome will also have acquired epige-
netic changes with an altered chromatin structure and gene
expression [185].
7. Conclusion
It could be concluded that cancer cells acquire the ability
to invade the host organism through the recapitulation of
extraembryonic, amniotic, and vitelline functions. In this
way, through the hypothesized overlapping expression of
these two extraembryonic functional axes, cancer cells would
adopt the diﬀerent phenotypes that they need to develop.
Maybe this is the reason why pluripotent cancer-initiating
cells would acquire the nature of embryonic cells. Thus,
the cancer-initiating cells would have the amazing ability of
inducing, for their own beneﬁt, the expression in the host of
functional extraembryonic mechanisms.
The immunological properties of the extraembryonic
functions would have the aim of inducing the acceptance of
the embryo by the maternal immune system. In addition, the
adoption during the postnatal life of the above-mentioned
extraembryonic functions for developing new tissues during
wound repair and tumorigenesis could have the same objec-
tive. Therefore, an appropriate immunological and trophic
microenvironment would be created for coexisting with the
host.
Since the tumor tissue is what induces the expression of
extraembryonic functions in the host that favor its devel-
opment, it would become an autonomous organism that
progressively takes over its nutritional stores. This behavior
could be compared with how the cuckoo adapts for repro-
duction. This bird uses foreign nests to lay its eggs, which
will be incubated by other birds. After hitching, the newborn
cuckoos throw out all potential competitors from the nest
and thus monopolize the nutritional support of the deceived
parents. In the same way, tumor cells act selﬁshly, com-
pared to the altruistic behavior characteristic of the normal
cells of the host. Hence, in cancer, new immunotolerant
tissuesmonopolize thenutritional resourcesofthehost.This
behavior could represent a last attempt to survive this
indomitable eukaryotic cell even at the expense of “murder-
ing” its supporter.
Abbreviations
Angs: Angiopoietins
bFGF: Basic ﬁbroblast growth factor
EMT: Epithelial to mesenchymal transitions
ERKs: Extracellular signal-regulated kinases
FGF-2: Fibroblast growth factor-2
HDL: High-density lipoproteins
HGF: Hepatocyte growth factor
HIF: Hypoxia-inducible transcription
factorsystem
IKK: IκB kinase
IKK/NF-κB: IκB kinase/Nuclear factor kappa B system
JNKs: c-Jun NH2-terminal kinasesJournal of Oncology 15
MAPKs: Mitogen activated protein kinases
MET: Mesenchymal to epithelial transition
mTOR: Mammalian target of rapamycin
NF-κB: Nuclear factor kappa B
PCI3K: Phosphoinositide 3-kinase
PDGF: Platelet-derived growth factor
PHDs: Prolyl hydroxylases
PTEN: Phosphatase and tensin homolog
Shh: Sonic hedgehog
SIRS: Systemic inﬂammatory response syndrome
TAMs: Inﬁltrating tumor associated macrophages
TGF-β: Transforming growth factor β
TLR: Toll-like receptors
VEGF-A: Vascular endothelial growth factor A
VLDL: Very- low-density lipoproteins.
Acknowledgments
The authors would like to thank Maria-Elena Vicente for
preparing the manuscript, Elizabeth Mascola for translating
it into English, and the Complutense University Medical
School Director Chief Section librarians, Juan-Carlos Dom-
inguezandMar´ ıa-Jos´ eV aldemor o .Thisw orkwassupported,
inpart,byaGrantfromtheMutuaMadrile˜ naAutomovilista,
Reference no. AP6977/2009.
References
[1] A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-
related inﬂammation,” Nature, vol. 454, no. 7203, pp. 436–
444, 2008.
[2] H. F. Dvorak, “Tumors: wounds that do not heal: similarities
between tumor stroma generation and wound healing,” New
England Journal of Medicine, vol. 315, no. 26, pp. 1650–1659,
1986.
[ 3 ]M .M .M o o r e ,W .C h u a ,K .A .C h a r l e s ,a n dS .J .C l a r k e ,“ I n -
ﬂammation and cancer: causes and consequences,” Clinical
Pharmacology and Therapeutics, vol. 87, no. 4, pp. 504–508,
2010.
[4] M. Sch¨ afer and S. Werner, “Cancer as an overhealing wound:
an old hypothesis revisited,” Nature Reviews Molecular Cell
Biology, vol. 9, no. 8, pp. 628–638, 2008.
[ 5 ]M .A .A l l e r ,J .L .A r i a s ,M .P .N a v a ,a n dJ .A r i a s ,“ P o s t -
traumatic inﬂammation is a complex response based on the
pathological expression of the nervous, immune, and endo-
crine functional systems,” Experimental Biology and Medi-
cine, vol. 229, no. 2, pp. 170–181, 2004.
[ 6 ]M .A .A l l e r ,J .I .A r i a s ,M .G i n e re ta l . ,“ O x y g e n - r e l a t e di n -
ﬂammatory wound phenotypes,” in Wound Healing: Process,
Phases and Promoting,J .E .M i d d l e t o n ,E d . ,c h a p t e r2 ,p p .1 –
26, Nova Science Publishers, Huntington, NY, USA, 2011.
[ 7 ]M .A .A l l e r ,J .L .A r i a s ,F .S ´ anchez-Pat´ an, and J. Arias, “The
inﬂammatory response: an eﬃcient way of life,” Medical
Science Monitor, vol. 12, no. 10, pp. RA225–RA234, 2006.
[ 8 ]M .A .A l l e r ,J .I .A r i a s ,a n dJ .A r i a s ,“ P a t h o l o g i c a la x e so f
wound repair: gastrulation revisited,” Theoretical Biology and
Medical Modelling, vol. 7, no. 1, article 37, pp. 1–32, 2010.
[9] M. P. De-Miguel, F. Arnalich-Montiel, P. Lopez-Iglesias, A.
Blazquez-Martinez, and M. Nistal, “Epiblast-derived stem
cells in embryonic and adult tissues,” International Journal
of Developmental Biology, vol. 53, no. 8–10, pp. 1529–1540,
2009.
[10] C.Bellini,F.Boccardo,E.Bonioli,andC.Campisi,“Lympho-
dynamicsinthefetusandnewborn,”Lymphology, vol.39,no.
3, pp. 110–117, 2006.
[11] M. A. Underwood, W. M. Gilbert, and M. P. Sherman, “Am-
niotic ﬂuid: not just fetal urine anymore,” Journal of Perina-
tology, vol. 25, no. 5, pp. 341–348, 2005.
[12] B. J. Kim, R. Romero, S. M. Lee et al., “Clinical signiﬁcance
of oligohydramnios in patients with preterm labor and intact
membranes∗,∗∗,” Journal of Perinatal Medicine, vol. 39, no.
2, pp. 131–136, 2011.
[13] O. Parolini, M. Soncini, M. Evangelista, and D. Schmidt,
“Amniotic membrane and amniotic ﬂuid-derived cells: po-
tential tools for regenerative medicine?” Regenerative Medi-
cine, vol. 4, no. 2, pp. 275–291, 2009.
[14] M. Bielinska, N. Narita, and D. B. Wilson, “Distinct roles for
visceral endoderm during embryonic mouse development,”
International Journal of Developmental Biology, vol. 43, no. 3,
pp. 183–205, 1999.
[15] S. Collardeau-Frachon and J. Y. Scoazec, “Vascular develop-
ment and diﬀerentiation during human liver organogenesis,”
Anatomical Record, vol. 291, no. 6, pp. 614–627, 2008.
[16] S. Yoshida and Y. Wada, “Transfer of maternal cholesterol
to embryo and fetus in pregnant mice,” Journal of Lipid
Research, vol. 46, no. 10, pp. 2168–2174, 2005.
[17] S. Koike, K. Keino-Masu, T. Ohto, F. Sugiyama, S. Takahashi,
and M. Masu, “Autotaxin/lysophospholipase D-mediated ly-
sophosphatidic acid signaling is required to form distinctive
large lysosomes in the visceral endoderm cells of the mouse
yolk Sac,” Journal of Biological Chemistry, vol. 284, no. 48, pp.
33561–33570, 2009.
[18] Y. Terasawa, S. J. Cases, J. S. Wong et al., “Apolipoprotein B-
related gene expression and ultrastructural characteristics of
lipoprotein secretion in mouse yolk sac during embryonic
development,” Journal of Lipid Research, vol. 40, no. 11, pp.
1967–1977, 1999.
[19] P.Rantakari,H.Lagerbohm,M.Kaimainenetal.,“Hydroxys-
teroid (17β) dehydrogenase 12 is essential for mouse organo-
genesis and embryonic survival,” Endocrinology, vol. 151, no.
4, pp. 1893–1901, 2010.
[ 2 0 ]A .A r u k w ea n dA .G o k s ø y r ,“ E g g s h e l la n de g gy o l kp r o t e i n s
in ﬁsh: hepatic proteins for the next generation: oogenetic,
population, and evolutionary implications of endocrine dis-
ruption,” Comparative Hepatology, vol. 2, no. 1, article 4,
2003.
[21] J. M. Sorrell and A. I. Caplan, “Fibroblasts-a diverse popula-
tion at the center of it all,” International Review of Cell and
Molecular Biology, vol. 276, no. C, pp. 161–214, 2009.
[22] B. Hinz, “The myoﬁbroblast: paradigm for a mechanically
active cell,” Journal of Biomechanics, vol. 43, no. 1, pp. 146–
155, 2010.
[ 2 3 ]D .P i l l i n g ,T .F a n ,D .H u a n g ,B .K a u l ,a n dR .H .G o m e r ,
“Identiﬁcationofmarkersthatdistinguishmonocyte-derived
ﬁbrocytes from monocytes, macrophages, and ﬁbroblasts,”
PLoS ONE, vol. 4, no. 10, Article ID e7475, 2009.
[24] N. Seta and M. Kuwana, “Human circulating monocytes as
multipotential progenitors,” Keio Journal of Medicine, vol. 56,
no. 2, pp. 41–47, 2007.
[ 2 5 ]B .E c k e r s ,R .N i s c h t ,a n dT .K r i e g ,“ C e l l - m a t r i xi n t e r a c t i o n s
indermalrepairandscarring,”FibrogenesisTissueRepair,vol.
3, p. 4, 2010.
[26] C. K. Sen, “Wound healing essentials: let there be oxygen,”
Wound Repair and Regeneration, vol. 17, no. 1, pp. 1–18,
2009.16 Journal of Oncology
[27] H. M. Chung, C. H. Won, and J. H. Sung, “Responses of
adipose-derived stem cells during hypoxia: enhanced skin-
regenerativepotential,”ExpertOpiniononBiologicalTherapy,
vol. 9, no. 12, pp. 1499–1508, 2009.
[28] G. C. Gurtner, S. Werner, Y. Barrandon, and M. T. Longaker,
“Wound repair and regeneration,” Nature, vol. 453, no. 7193,
pp. 314–321, 2008.
[29] R. Kalluri and R. A. Weinberg, “The basics of epithelial-mes-
enchymal transition,” Journal of Clinical Investigation, vol.
119, no. 6, pp. 1420–1428, 2009.
[30] M. Selman, A. Pardo, and N. Kaminski, “Idiopathic pul-
monary ﬁbrosis: aberrant recapitulation of developmental
programs?” PLoS Medicine, vol. 5, no. 3, article e62, 2008.
[31] T. L. Whiteside, “The tumor microenvironment and its role
in promoting tumor growth,” Oncogene, vol. 27, no. 45, pp.
5904–5912, 2008.
[32] J. Kluwe, A. Mencin, and R. F. Schwabe, “Toll-like receptors,
wound healing, and carcinogenesis,” Journal of Molecular
Medicine, vol. 87, no. 2, pp. 125–138, 2009.
[33] S. A. Patel, A. C. Heinrich, B. Y. Reddy, and P. Rameshwar,
“Inﬂammatory mediators: parallels between cancer biology
and stem cell therapy,” Journal of Inﬂammation Research, vol.
1, no. 2, pp. 13–19, 2009.
[34] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity,
inﬂammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899,
2010.
[35] J. Rodriguez-Vita and T. Lawrence, “The resolution of in-
ﬂammationandcancer,”CytokineandGrowthFactorReviews,
vol. 21, no. 1, pp. 61–65, 2010.
[36] A. J. Schetter, N. H. H. Heegaard, and C. C. Harris, “Inﬂam-
mation and cancer: interweaving microRNA, free radical,
cytokine and p53 pathways,” Carcinogenesis, vol. 31, no. 1,
Article ID bgp272, pp. 37–49, 2010.
[37] M. Allen and J. L. Jones, “Jekyll and Hyde: the role of the
microenvironment on the progression of cancer,” Journal of
Pathology, vol. 223, no. 2, pp. 162–176, 2011.
[38] L. C. Costello and R. B. Franklin, “Tumor cell metabolism:
the marriage of molecular genetics and proteomics with cel-
lular intermediary metabolism; proceed with caution!,” Mo-
lecular Cancer, vol. 5, no. 7, article 59, 2006.
[39] P. Dalerba, R. W. Cho, and M. F. Clarke, “Cancer stem cells:
modelsandconcepts,”AnnualReviewofMedicine,vol.58,pp.
267–284, 2007.
[ 4 0 ] J .E .V i s v a d e r ,“ C e l l so fo ri gi ni nc a n c e r , ”Nature, vol. 469, no.
7330, pp. 314–322, 2011.
[41] R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou, and C. B.
Thompson, “The biology of cancer: metabolic reprogram-
ming fuels cell growth and proliferation,” Cell Metabolism,
vol. 7, no. 1, pp. 11–20, 2008.
[42] C. V. Dang, M. Hamaker, P. Sun, A. Le, and P. Gao, “Thera-
peutic targeting of cancer cell metabolism,” Journal of Molec-
ular Medicine, vol. 89, no. 3, pp. 205–212, 2011.
[43] N. P. Shanware, A. R. Mullen, R. J. DeBerardinis, and R. T.
Abraham,“Glutamine:pleiotropicrolesintumorgrowthand
stress resistance,” Journal of Molecular Medicine, vol. 89, no.
3, pp. 229–236, 2011.
[44] J. I. Arias, M. A. Aller, and J. Arias, “The use of inﬂammation
by tumor cells,” Cancer, vol. 104, no. 2, pp. 223–228, 2005.
[45] J.I.Arias,M.A.Aller,F.S´ anchez-Patan,andJ.Arias,“Inﬂam-
mation and cancer: is trophism the link?” Surgical Oncology,
vol. 15, no. 4, pp. 235–242, 2006.
[46] J.I.Arias,M.A.Aller,andJ.Arias,“Cancercell:usinginﬂam-
mation to invade the host,” Molecular Cancer, vol. 6, article
29, 2007.
[47] A. Bishop, “Role of oxygen in wound healing,” Journal of
Wound Care, vol. 17, no. 9, pp. 399–402, 2008.
[48] S. Schreml, R. M. Szeimies, L. Prantl, S. Karrer, M. Land-
thaler, and P. Babilas, “Oxygen in acute and chronic wound
healing,” British Journal of Dermatology, vol. 163, no. 2, pp.
257–268, 2010.
[49] M. Mareel and A. Leroy, “Clinical, cellular, and molecular
aspects of cancer invasion,” Physiological Reviews, vol. 83, no.
2, pp. 337–376, 2003.
[50] H. K. Eltzschig and P. Carmeliet, “Hypoxia and inﬂamma-
tion,” New England Journal of Medicine, vol. 364, no. 7, pp.
656–665, 2011.
[ 5 1 ]A .B a m i a sa n dM .A .D i m o p o u l o s ,“ A n g i o g e n e s i si nh u m a n
cancer: implications in cancer therapy,” European Journal of
Internal Medicine, vol. 14, no. 8, pp. 459–469, 2003.
[52] N. C. Denko, L. A. Fontana, K. M. Hudson et al., “Inves-
tigating hypoxic tumor physiology through gene expression
patterns,” Oncogene, vol. 22, no. 37, pp. 5907–5914, 2003.
[53] M.G.V .H eiden,L.C.Cantley ,andC.B.Thompson,“U nder -
standing the warburg eﬀe c t :t h em e t a b o l i cr e q u i r e m e n t so f
cell proliferation,” Science, vol. 324, no. 5930, pp. 1029–1033,
2009.
[54] W. Hornebeck, H. Emonard, J. C. Monboisse, and G. Bellon,
“Matrix-directed regulation of pericellular proteolysis and
tumor progression,” Seminars in Cancer Biology, vol. 12, no.
3, pp. 231–241, 2002.
[55] C. Gialeli, A. D. Theocharis, and N. K. Karamanos, “Roles
of matrix metalloproteinases in cancer progression and their
pharmacological targeting,” FEBS Journal, vol. 278, no. 1, pp.
16–27, 2011.
[56] O. Schmidt-Kittler, T. Ragg, A. Daskalakis et al., “From latent
disseminated cells to overt metastasis: genetic analysis of sys-
temic breast cancer progression,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 13, pp. 7737–7742, 2003.
[57] I. Freitas, G. F. Baronzio, B. Bono et al., “Tumor interstitial
ﬂuid: misconsidered component of the internal milieu of a
solid tumor,” Anticancer Research, vol. 17, no. 1 A, pp. 165–
172, 1997.
[58] M.EisenhutandH.Wallace,“Ionchannelsininﬂammation,”
Pﬂugers Archiv European Journal of Physiology, vol. 461, no. 4,
pp. 401–421, 2011.
[ 5 9 ] H .W i i g ,O .T e n s t a d ,P . O .I v e r s e n ,R .K a l l u r i ,a n dR .B j e r k v i g ,
“Interstitial ﬂuid: the overlooked component of the tumor
microenvironment?” Fibrogenesis and Tissue Repair, vol. 3, p.
12, 2010.
[60] A. C. Shieh and M. A. Swartz, “Regulation of tumor invasion
by interstitial ﬂuid ﬂow,” Physical Biology,v o l .8 ,n o .1 ,p p .
1–8, 2011.
[61] P. -N. Teng, B. L. Hood, M. Sun, R. Dhir, and T. P. Conrads,
“Diﬀerentialproteomicanalysisofrenalcellcarcinomatissue
interstitial ﬂuid,” Journal of Proteome Research, vol. 10, no. 3,
pp. 1333–1342, 2011.
[62] L. Ronnov-Jessen, O. W. Petersen, and M. J. Bissell, “Cellular
changes involved in conversion of normal to malignant
breast: importance of the stromal reaction,” Physiological Re-
views, vol. 76, no. 1, pp. 69–125, 1996.
[63] D. Jiang, J. Liang, and P. W. Noble, “Hyaluronan in tissue
injury and repair,” Annual Review of Cell and Developmental
Biology, vol. 23, pp. 435–461, 2007.
[ 6 4 ] B .C h e na n dB .F u ,“ Am o d e lf o rc h a r g e dm o l e c u l et r a n s p o r t
in the interstitial space,” in Proceedings of the 27th Annual In-
ternational Conference of the Engineering in Medicine andJournal of Oncology 17
Biology Society (IEEE-EMBS ’05), vol. 1, no. 1, pp. 55–58,
September 2005.
[65] L. N. Cueni and M. Detmar, “The lymphatic system in health
and disease,” Lymphatic Research and Biology, vol. 6, no. 3-4,
pp. 109–122, 2008.
[66] J. M. Rutkowski and M. A. Swartz, “A driving force for
change: interstitial ﬂow as a morphoregulator,” Trends in Cell
Biology, vol. 17, no. 1, pp. 44–50, 2007.
[67] M. Nagahashi, S. Ramachandran, O. M. Rashid, and K.
Takabe,“Lymphangiogenesis:anewplayerincancerprogres-
sion,” World Journal of Gastroenterology, vol. 16, no. 32, pp.
4003–4012, 2010.
[68] Z. Zhang, J. I. Helman, and L. J. Li, “Lymphangiogenesis,
lymphatic endothelial cells and lymphatic metastasis in head
and neck cancer–a review of mechanisms,” International
J o u r n a lo fO r a lS c i e n c e , vol. 2, no. 1, pp. 5–14, 2010.
[69] A. W. Lund and M. A. Swartz, “Role of lymphatic vessels in
tumor immunity: passive conduits or active participants?”
Journal of Mammary Gland Biology and Neoplasia, vol. 15,
no. 3, pp. 341–352, 2010.
[70] M. A. Al-Rawi and W. G. Jiang, “Lymphangiogenesis and
cancer metastasis,” Frontiers in Bioscience, vol. 16, no. 2, pp.
723–739, 2011.
[71] B. Halliwell, “Oxidative stress and cancer: have we moved
forward?”BiochemicalJournal,vol.401,no.1,pp.1–11,2007.
[72] G. He and M. Karin, “NF-κB and STAT3- key players in liver
inﬂammation and cancer,” Cell Research, vol. 21, no. 1, pp.
159–168, 2011.
[73] T. Hanada and A. Yoshimura, “Regulation of cytokine signal-
ing and inﬂammation,” Cytokine and Growth Factor Reviews,
vol. 13, no. 4-5, pp. 413–421, 2002.
[74] S. A. Patel, A.C. Heinrich, B. Y. Reddy, and P. Rameshwar,
“Inﬂammatory mediators: parallels between cancer biology
and stem cell therapy,” Journal of Inﬂammation Research, vol.
2, pp. 13–19, 2009.
[75] S. Rakoﬀ-Nahoum and R. Medzhitov, “Toll-like receptors
and cancer,” Nature Reviews Cancer, vol. 9, no. 1, pp. 57–63,
2009.
[76] D. Wang and R. N. Dubois, “Eicosanoids and cancer,” Nature
Reviews Cancer, vol. 10, no. 3, pp. 181–193, 2010.
[77] P. Huang, J. Han, and L. Hui, “MAPK signaling in inﬂamma-
tion-associated cancer development,” Protein Cell, vol. 1, no.
3, pp. 218–228, 2010.
[78] M. Peyrou, L. Bourgoin, and M. Foti, “PTEN in liver diseases
andcancer,”WorldJournalofGastroenterology,vol.16,no.37,
pp. 4627–4633, 2010.
[79] M. Philip, D. A. Rowley, and H. Schreiber, “Inﬂammation as
a tumor promoter in cancer induction,” Seminars in Cancer
Biology, vol. 14, no. 6, pp. 433–439, 2004.
[80] A. Ben-Baruch, “Inﬂammation-associated immune suppres-
sion in cancer: the roles played by cytokines, chemokines and
additional mediators,” Seminars in Cancer Biology, vol. 16,
no. 1, pp. 38–52, 2006.
[81] B. J. Nickoloﬀ, Y. Ben-Neriah, and E. Pikarsky, “Inﬂamma-
tion and cancer: is the link as simple as we think?” Journal of
Investigative Dermatology, vol. 124, no. 6, pp. 10–14, 2005.
[82] K. Palucka, H. Ueno, J. Fay, and J. Banchereau, “Dendritic
cells and immunity against cancer,” Journal of Internal Medi-
cine, vol. 269, no. 1, pp. 64–73, 2011.
[83] A. Mantovani and A. Sica, “Macrophages, innate immunity
and cancer: balance, tolerance, and diversity,” Current Opin-
ion in Immunology, vol. 22, no. 2, pp. 231–237, 2010.
[84] F. Balkwill and A. Mantovani, “Cancer and inﬂammation:
implications for pharmacology and therapeutics,” Clinical
Pharmacology and Therapeutics, vol. 87, no. 4, pp. 401–406,
2010.
[85] P. Mishra, D. Banerjee, and A. Ben-Baruch, “Chemokines at
the crossroads of tumor-ﬁbroblast interactions that promote
malignancy,” Journal of Leukocyte Biology, vol. 89, no. 1, pp.
31–39, 2010.
[86] A. Sica, “Role of tumour-associated macrophages in cancer-
related inﬂammation,” Experimental Oncology, vol. 32, no. 3,
pp. 153–158, 2010.
[87] C. Chetty, J. S. Rao, and S. S. Lakka, “Matrix metalloprote-
inase pharmacogenomics in non-small-cell lung carcinoma,”
Pharmacogenomics, vol. 12, no. 4, pp. 535–546, 2011.
[88] J. A. Engbring and H. K. Kleinman, “The basement mem-
brane matrix in malignancy,” Journal of Pathology, vol. 200,
no. 4, pp. 465–470, 2003.
[89] A.M¨ uller,B.Homey,H.Sotoetal.,“Involvementofchemok-
ine receptors in breast cancer metastasis,” Nature, vol. 410,
no. 6824, pp. 50–56, 2001.
[90] M. A. A. Al-Rawi, R. E. Mansel, and W. G. Jiang, “Lymphan-
giogenesis and its role in cancer,” Histology and Histopathol-
ogy, vol. 20, no. 1, pp. 283–298, 2005.
[91] S. Kraljevic Pavelic, M. Sedic, H. Bosnjak, S. Spaventi, and
K. Pavelic, “Metastasis: new perspectives on an old problem,”
Molecular Cancer, vol. 10, article 22, 2011.
[92] M. V. Sitkovsky, D. Lukashev, S. Apasov et al., “Physiolog-
ical control of immune response and inﬂammatory tissue
damage by hypoxia-inducible factors and adenosine A2A
receptors,” Annual Review of Immunology, vol. 22, pp. 657–
682, 2004.
[93] A. J. Levine and A. M. Puzio-Kuter, “The control of the
metabolic switch in cancers by oncogenes and tumor sup-
pressor genes,” Science, vol. 330, no. 6009, pp. 1340–1344,
2010.
[94] A. -F.A. Mentis and E. Kararizou, “Metabolism and cancer:
an up-to-date review of a mutual connection,” Asian Paciﬁc
Journal of Cancer Prevention, vol. 11, no. 6, pp. 1437–1444,
2010.
[95] K. N. Naresh, A. Y. Nerurkar, and A. M. Borges, “Angio-
genesis is redundant for tumour growth in lymph node
metastases,”Histopathology, vol.38,no.5,pp.466–470,2001.
[96] J. P. Sleeman, I. Nazarenko, and W. Thiele, “Do all roads lead
to Rome? Routes to metastasis development,” International
Journal of Cancer, vol. 128, no. 11, pp. 2511–2526, 2011.
[97] S. Chouaib, C. Kieda, H. Benlalam, M. Z. Noman, F. Mami-
Chouaib, and C. R¨ uegg, “Endothelial cells as key determi-
nants of the tumor microenvironment: interaction with tu-
mor cells, extracellular matrix and immune killer cells,” Crit-
ical Reviews in Immunology, vol. 30, no. 6, pp. 529–545, 2010.
[98] J. P. Sleeman and W. Thiele, “Tumor metastasis and the
lymphatic vasculature,” International Journal of Cancer, vol.
125, no. 12, pp. 2747–2756, 2009.
[99] R. -C. Ji, “Lymph node lymphangiogenesis: a new concept
formodulatingtumormetastasisandinﬂammatoryprocess,”
Histology and Histopathology, vol. 24, no. 3, pp. 377–384,
2009.
[100] K. Pantel and U. Woelﬂe, “Detection and molecular char-
acterisation of disseminated tumor cells: implications for
anticancer therapy,” Biochimica et Biophysica Acta, vol. 1756,
no. 1, pp. 53–64, 2005.
[101] S. Braun, C. Kentenich, W. Janni et al., “Lack of eﬀect of ad-
juvant chemotherapy on the elimination of single dormant
tumor cells in bone marrow of high-risk breast cancer pa-
tients,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 80–86,
2000.18 Journal of Oncology
[102] T.Tammela,A.Saaristo,T.Holopainenetal.,“Photodynamic
ablation of lymphatic vessels and intralymphatic cancer cells
prevents metastasis,” Science Translational Medicine, vol. 3,
no. 69, Article ID 69ra11, 2011.
[103] C. Deans and S. J. Wigmore, “Systemic inﬂammation, cach-
exia and prognosis in patients with cancer,” Current Opinion
in Clinical Nutrition and Metabolic Care,v o l .8 ,n o .3 ,p p .
265–269, 2005.
[104] M. J. Delano and L. L. Moldawer, “The origin of cachexia in
acute and chronic inﬂammatory diseases,” Nutrition in Clin-
ical Practice, vol. 21, no. 1, pp. 68–81, 2006.
[105] K. Fearon, F. Strasser, S. D. Anker et al., “Deﬁnition and
classiﬁcation of cancer cachexia: an international consensus,”
The Lancet Oncology, vol. 12, no. 5, pp. 489–495, 2011.
[106] C. C. Clement, O. Rotzschke, and L. Santambrogio, “The
lymph as a pool of self-antigens,” Trends in Immunology, vol.
32, no. 1, pp. 6–11, 2011.
[107] F. Bruy` ere and A. No¨ el, “Lymphangiogenesis: in vitro and in
vivo models,” FASEB Journal, vol. 24, no. 1, pp. 8–21, 2010.
[108] O. Thaunat, D. Kerjaschki, and A. Nicoletti, “Is defective
lymphatic drainage a trigger for lymphoid neogenesis?”
Trends in Immunology, vol. 27, no. 10, pp. 441–445, 2006.
[109] T. Condamine and D. I. Gabrilovich, “Molecular mecha-
nisms regulating myeloid-derived suppressor cell diﬀerenti-
ation and function,” Trends in Immunology, vol. 32, no. 1, pp.
19–25, 2011.
[110] B. M. Delavary, W. M. van der Veer, M. van Egmond, F. B.
Niessen, and R. H.J. Beelen, “Macrophages in skin injury and
repair,” Immunobiology, vol. 216, no. 7, pp. 753–762, 2011.
[111] S. R. Goldberg and R. F. Diegelmann, “Wound healing prim-
er,” Surgical Clinics of North America, vol. 90, no. 6, pp. 1133–
1146, 2010.
[112] B. Shih, E. Garside, D. A. McGrouther, and A. Bayat, “Molec-
ular dissection of abnormal wound healing processes result-
ing in keloid disease,” Wound Repair and Regeneration, vol.
18, no. 2, pp. 139–153, 2010.
[113] Y. Wu, R. C. H. Zhao, and E. E. Tredget, “Concise review:
bone marrow-derived stem/progenitor cells in cutaneous re-
pairandregeneration,”StemCells,vol.28,no.5,pp.905–915,
2010.
[114] H. Acloque, M. S. Adams, K. Fishwick, M. Bronner-Fraser,
and M. A. Nieto, “Epithelial-mesenchymal transitions: the
importance of changing cell state in development and
disease,” Journal of Clinical Investigation, vol. 119, no. 6, pp.
1438–1449, 2009.
[115] M. Sioud, “New insights into mesenchymal stromal cell-
mediated T-cell suppression through galectins,” Scandina-
vian Journal of Immunology, vol. 73, no. 2, pp. 79–84, 2011.
[116] K. Norrby, “In vivo models of angiogenesis,” Journal of Cellu-
lar and Molecular Medicine, vol. 10, no. 3, pp. 588–612, 2006.
[117] D. Fukumura, D. G. Duda, L. L. Munn, and R. K. Jain, “Tu-
mormicrovasculature andmicroenvironment: novelinsights
through intravital imaging in pre-clinical models,” Microcir-
culation, vol. 17, no. 3, pp. 206–225, 2010.
[118] R. Van Horssen, T. L. M. Ten Hagen, and A. M. M. Egger-
mont, “TNF-α in cancer treatment: molecular insights, anti-
tumor eﬀects, and clinical utility,” Oncologist,v o l .1 1 ,n o .4 ,
pp. 397–408, 2006.
[119] A.M.Byrne,D.J.Bouchier-Hayes,andJ.H.Harmey,“Angio-
genic and cell survival functions of Vascular Endothelial
Growth Factor (VEGF),” Journal of Cellular and Molecular
Medicine, vol. 9, no. 4, pp. 777–794, 2005.
[120] R. Kalluri and M. Zeisberg, “Fibroblasts in cancer,” Nature
Reviews Cancer, vol. 6, no. 5, pp. 392–401, 2006.
[121] I. L. Grigorova, M. Panteleev, and J. G. Cyster, “Lymph node
cortical sinus organization and relationship to lymphocyte
egress dynamics and antigen exposure,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 107, no. 47, pp. 20447–20452, 2010.
[122] H. Hayasaka, K. Taniguchi, S. Fukai, and M. Miyasaka,
“Neogenesisanddevelopmentofthehighendothelialvenules
that mediate lymphocyte traﬃcking,” Cancer Science, vol.
101, no. 11, pp. 2302–2308, 2010.
[123] X. Bao, E. A. Moseman, H. Saito et al., “Endothelial heparan
sulfate controls chemokine presentation in recruitment of
lymphocytes and dendritic cells to lymph nodes,” Immunity,
vol. 33, no. 5, pp. 817–829, 2010.
[124] E. Favaro, A. Amadori, and S. Indraccolo, “Cellular interac-
tions in the vascular niche: implications in the regulation of
tumor dormancy,” Acta Pathologica, Microbiologica et Immu-
nologica Scandinavica, vol. 116, no. 7-8, pp. 648–659, 2008.
[125] M. Pinto, P. Soares, and D. Ribatti, “Thyroid hormone as a
regulatoroftumorinducedangiogenesis,”CancerLetters,vol.
301, no. 2, pp. 119–126, 2011.
[126] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the
next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[127] R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of
cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no.
2, pp. 85–95, 2011.
[128] H. Nakamura and A. Hase, “Cellular diﬀerentiation in the
process of generation of the eukaryotic cell,” Origins of Life
and Evolution of the Biosphere, vol. 20, no. 6, pp. 499–514,
1990.
[129] P.Goldsmith,H.Fenton,G.Morris-Stiﬀ,N.Ahmad,J .Fisher ,
and K.R. Prasad, “Metabonomics: a useful tool for the future
surgeon,” Journal of Surgical Research, vol. 160, no. 1, pp.
122–132, 2010.
[130] N. J. Serkova, J. L. Spratlin, and S. G. Eckhardt, “NMR-
based metabolomics: translational application and treatment
of cancer,” Current Opinion in Molecular Therapeutics, vol. 9,
no. 6, pp. 572–585, 2007.
[131] A. Herling, M. K¨ onig, S. Bulik, and H. G. Holzh¨ utter, “En-
zymatic features of the glucose metabolism in tumor cells,”
FEBS Journal, vol. 278, no. 14, pp. 2436–2459, 2011.
[132] M. C. Brahimi-Horn, J. Chiche, and J. Pouyss´ egur, “Hypoxia
andcancer,”JournalofMolecularMedicine,vol.85,no.12,pp.
1301–1307, 2007.
[133] S. Matsumoto, H. Yasui, J. B. Mitchell, and M. C. Krishna,
“Imaging cycling tumor hypoxia,” Cancer Research, vol. 70,
no. 24, pp. 10019–10023, 2010.
[134] L. De Filippis and D. Delia, “Hypoxia in the regulation of
neural stem cells,” Cellular and Molecular Life Sciences, vol.
68, no. 17, pp. 2831–2844, 2011.
[135] M. T. Stockhausen, K. Kristoﬀe r s e n ,a n dH .S .P o u l s e n ,“ T h e
functionalroleofNotchsignalinginhumangliomas,”Neuro-
Oncology, vol. 12, no. 2, pp. 199–211, 2010.
[136] T. Pierfelice, L. Alberi, and N. Gaiano, “Notch in the verte-
brate nervous system: an old dog with new tricks,” Neuron,
vol. 69, no. 5, pp. 840–855, 2011.
[137] D. Subramaniam, S. Ramalingam, C. W. Houchen, and S.
Anant, “Cancer stem cells: a novel paradigm for cancer
prevention and treatment,” MiniReviewsin MedicinalChem-
istry, vol. 10, no. 5, pp. 359–371, 2010.
[138] S.Guo,M.Liu,andR.R.Gonzalez-Perez,“RoleofNotchand
its oncogenic signaling crosstalk in breast cancer,” Biochimica
et Biophysica Acta—Reviews on Cancer, vol. 1815, no. 2, pp.
197–213, 2011.Journal of Oncology 19
[139] N. Takebe, P. J. Harris, R. Q. Warren, and S. P. Ivy, “Targeting
cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways,”NatureReviewsClinicalOncology,v ol.8,no .2,pp .
97–106, 2011.
[140] K.Bartkowiak,S.Riethdorf,andK.Pantel,“Theinterrelating
dynamics of hypoxic tumor microenvironments and cancer
cell phenotypes in cancer metastasis,” Cancer Microenviron-
ment. In press.
[141] N. J. Kruger and A. Von Schaewen, “The oxidative pentose
phosphate pathway: structure and organisation,” Current
Opinion in Plant Biology, vol. 6, no. 3, pp. 236–246, 2003.
[142] A. Kr¨ uger and M. Ralser, “ATM is a redox sensor linking
genome stability and carbon metabolism,” Science Signaling,
vol. 4, no. 167, 2011.
[143] J. L. Yecies and B. D. Manning, “MTOR links oncogenic sig-
naling to tumor cell metabolism,” Journal of Molecular Medi-
cine, vol. 89, no. 3, pp. 221–228, 2011.
[144] A. Perl, R. Hanczko, T. Telarico, Z. Oaks, and S. Landas,
“Oxidative stress, inﬂammation and carcinogenesis are con-
trolled through the pentose phosphate pathway by transal-
dolase,” Trends in Molecular Medicine, vol. 17, no. 7, pp. 395–
403, 2011.
[145] J. J. Gibbons, R. T. Abraham, and K. Yu, “Mammalian target
of rapamycin: discovery of rapamycin reveals a signaling
pathway important for normal and cancer cell growth,”
Seminars in Oncology, vol. 36, no. 3, pp. S3–S17, 2009.
[146] J. L. Yecies and B. D. Manning, “Transcriptional control of
cellular metabolism by mtor signaling,” Cancer Research, vol.
71, no. 8, pp. 2815–2820, 2011.
[147] K. Zhang, L. Zhu, and M. Fan, “Oxygen, a key factor regulat-
ing cell behavior during neurogenesis and cerebral diseases,”
Frontiers in Molecular Neuroscience, vol. 4, no. 5, 2011.
[148] T. Kume, “Speciﬁcation of arterial, venous, and lymphatic
endothelial cells during embryonic development,” Histology
and Histopathology, vol. 25, no. 5, pp. 637–646, 2010.
[149] D. Morrow, J. P. Cullen, W. Liu et al., “Sonic hedgehog indu-
ces notch target gene expression in vascular smooth muscle
cells via VEGF-A,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 29, no. 7, pp. 1112–1118, 2009.
[150] M. Onimaru and Y. Yonemitsu, “Angiogenic and lymphan-
giogenic cascades in the tumor microenvironment,” Frontiers
in Bioscience, vol. 3, pp. 216–225, 2011.
[151] K.Takenaga,“Angiogenicsignalingaberrantlyinducedbytu-
mor hypoxia,” Frontiers in Bioscience, vol. 16, no. 1, pp. 31–
48, 2011.
[152] R. A. Burger, “Overview of anti-angiogenic agents in devel-
opment for ovarian cancer,” Gynecologic Oncology, vol. 121,
no. 1, pp. 230–238, 2011.
[153] S. Rodr´ ıguez-Enr´ ıquez, J. C. Gallardo-P´ erez, A. Mar´ ın-
Hern´ andez et al., “Oxidative phosphorylation as a target to
arrest malignant neoplasias,” Current Medicinal Chemistry,
vol. 18, no. 21, pp. 3156–3167, 2011.
[154] M. Isra¨ el and L. Schwartz, “The metabolic advantage of
tumor cells,” Molecular Cancer, vol. 10, 2011.
[155] A. Adinolﬁ, M. Adinolﬁ, and M. H. Lessof, “Alpha feto pro-
tein during development and in disease,” Journal of Medical
Genetics, vol. 12, no. 2, pp. 138–151, 1975.
[156] S. Sell and G. B. Pierce, “Maturation arrest of stem cell dif-
ferentiation is a common pathway for the cellular origin of
teratocarcinomas and epithelial cancers,” Laboratory Investi-
gation, vol. 70, no. 1, pp. 6–22, 1994.
[157] B. G. Brewer, R. A. Mitchell, A. Harandi, and J. W.
Eaton, “Embryonic vaccines against cancer: an early history,”
ExperimentalandMolecularPathology,vol.86,no.3,pp.192–
197, 2009.
[158] M. J. C. Hendrix, E. A. Seftor, R. E. B. Seftor, J. Kasemeier-
Kulesa, P. M. Kulesa, and L. M. Postovit, “Reprogramming
metastatic tumour cells with embryonic microenviron-
ments,” Nature Reviews Cancer, vol. 7, no. 4, pp. 246–255,
2007.
[159] L. Strizzi, K. M. Hardy, G. T. Kirsammer, P. Gerami, and M.
J.C. Hendrix, “Embryonic signaling in melanoma: potential
for diagnosis and therapy,” Laboratory Investigation, vol. 91,
no. 6, pp. 819–824, 2011.
[160] R. F. Diegelmann and M. C. Evans, “Wound healing: an
overview of acute, ﬁbrotic and delayed healing,” Frontiers in
Bioscience, vol. 9, pp. 283–289, 2004.
[161] A. Detoraki, F. Granata, S. Staibano, F. W. Rossi, G. Marone,
and A. Genovese, “Angiogenesis and lymphangiogenesis in
bronchial asthma,” Allergy, vol. 65, no. 8, pp. 946–958, 2010.
[162] U. Klueh, M. Kaur, Y. Qiao, and D. L. Kreutzer, “Critical role
of tissue mast cells in controlling long-term glucose sensor
function in vivo,” Biomaterials, vol. 31, no. 16, pp. 4540–
4551, 2010.
[163] W. M. Van Der Veer, M. C. Bloemen, M. M. Ulrich et al.,
“Potential cellular and molecular causes of hypertrophic scar
formation,” Burns, vol. 35, no. 1, pp. 15–29, 2009.
[164] F. Dazzi and M. Krampera, “Mesenchymal stem cells and
autoimmune diseases,” Best Practice and Research: Clinical
Haematology, vol. 24, no. 1, pp. 49–57, 2011.
[165] L. Yang, Y. Pang, and H. L. Moses, “TGF-β and immune cells:
animportantregulatoryaxisinthetumormicroenvironment
and progression,” Trends in Immunology, vol. 31, no. 6, pp.
220–227, 2010.
[166] M. F. Neurath and S. Finotto, “IL-6 signaling in autoim-
munity, chronic inﬂammation and inﬂammation-associated
cancer,” Cytokine and Growth Factor Reviews, vol. 22, no. 2,
pp. 83–89, 2011.
[167] I. Campbell, W. Qiu, and I. Haviv, “Genetic changes in tum-
our microenvironments,” Journal of Pathology, vol. 223, no.
4, pp. 450–458, 2011.
[168] L. da Silva Meirelles, A. M. Fontes, D. T. Covas, and A. I.
Caplan, “Mechanisms involved in the therapeutic properties
of mesenchymal stem cells,” C y t o k i n ea n dG r o w t hF a c t o r
Reviews, vol. 20, no. 5-6, pp. 419–427, 2009.
[169] T.S.Roh,D.K.Rah,andB.Y.Park,“Thefetalwoundhealing:
a review,” Yonsei Medical Journal, vol. 42, no. 6, pp. 630–633,
2001.
[170] B. J. Larson, M. T. Longaker, and H. P. Lorenz, “Scarless fetal
wound healing: a basic science review,” Plastic and Recon-
structive Surgery, vol. 126, no. 4, pp. 1172–1180, 2010.
[171] J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto,
“Epithelial-mesenchymal transitions in development and
disease,” Cell, vol. 139, no. 5, pp. 871–886, 2009.
[172] A. Singh and J. Settleman, “EMT, cancer stem cells and drug
resistance: an emerging axis of evil in the war on cancer,”
Oncogene, vol. 29, no. 34, pp. 4741–4751, 2010.
[173] Y.WangandH.Steinbeisser,“Molecularbasisofmorphogen-
esis during vertebrate gastrulation,” Cellular and Molecular
Life Sciences, vol. 66, no. 14, pp. 2263–2273, 2009.
[174] M. C. Simon and B. Keith, “The role of oxygen availability
in embryonic development and stem cell function,” Nature
Reviews Molecular Cell Biology, vol. 9, no. 4, pp. 285–296,
2008.
[175] Y. J. Chang, S. M. Hwang, C. P. Tseng et al., “Isolation
of mesenchymal stem cells with neurogenic potential from20 Journal of Oncology
the mesoderm of the amniotic membrane,” Cells Tissues Or-
gans, vol. 192, no. 2, pp. 93–105, 2010.
[176] S. Pfeiﬀer and D. McLaughlin, “In vitro diﬀerentiation of
human amniotic ﬂuid-derived cells: augmentation towards
a neuronal dopaminergic phenotype,” Cell Biology Interna-
tional, vol. 34, no. 9, pp. 959–967, 2010.
[177] H. Niknejad, H. Peirovi, M. Jorjani, A. Ahmadiani, J. Gha-
navi, and A. M. Seifalian, “Properties of the amniotic mem-
brane for potential use in tissue engineering,” European Cells
and Materials, vol. 15, no. 15, pp. 88–99, 2008.
[178] J. Y. Seong, M. Soncini, Y. Kaneko, D. C. Hess, O. Parolini,
and C. V. Borlongan, “Amnion: a potent graft source for cell
therapy in stroke,” Cell Transplantation,v o l .1 8 ,n o .2 ,p p .
111–118, 2009.
[179] M. G. Uberti, Y. N. Pierpont, F. Ko et al., “Amnion-derived
cellular cytokine solution (ACCS) promotes migration of ke-
ratinocytes and ﬁbroblasts,” Annals of Plastic Surgery, vol. 64,
no. 5, pp. 632–635, 2010.
[180] M. Gasperowicz and R. R. Natale, “Establishing Three Blas-
tocyst Lineages—Then What?” Biology of Reproduction, vol.
84, no. 4, pp. 621–630, 2009.
[181] S. T. Fraser and M. H. Baron, “Embryonic fates for extraem-
bryonic lineages: new perspectives,” Journal of Cellular Bio-
chemistry, vol. 107, no. 4, pp. 586–591, 2009.
[182] G. Sheng, “Primitive and deﬁnitive erythropoiesis in the yolk
sac: a bird’s eye view,” International Journal of Developmental
Biology, vol. 54, no. 6-7, pp. 1033–1043, 2010.
[183] E. S. Lander, “Initial impact of the sequencing of the human
genome,” Nature, vol. 470, no. 7333, pp. 187–197, 2011.
[184] J. P´ erez-Losada, A. Castellanos-Mart´ ın, and J. -H. Mao,
“Cancer evolution and individual susceptibility,” Integrative
Biology, vol. 3, no. 4, pp. 316–328, 2011.
[185] M. R. Stratton, P. J. Campbell, and P. A. Futreal, “The cancer
genome,” Nature, vol. 458, no. 7239, pp. 719–724, 2009.